_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expertdecision,relation,sent_id,sentence,term1,term2
497187298,7/2/2014 13:52:24,,1312957258,7/2/2014 13:51:49,neodev,1,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 14:30:05,,1312982364,7/2/2014 14:29:53,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 15:40:01,,1313025280,7/2/2014 15:39:43,instagc,1,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with LENNOX-GASTAUT SYNDROME,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 16:21:27,,1313051684,7/2/2014 16:21:13,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 16:31:33,,1313058589,7/2/2014 16:31:10,prodege,1,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with LENNOX-GASTAUT SYNDROME,n/a,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 17:38:07,,1313111556,7/2/2014 17:37:48,prodege,1,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],age,dsdssdsd,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 17:39:07,,1313112625,7/2/2014 17:38:36,prodege,1,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 17:52:00,,1313126796,7/2/2014 17:51:28,tremorgames,1,17552229,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],with,dsdsdsds,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 19:25:09,,1313215181,7/2/2014 19:24:45,prizezombie,1,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],associated with,NA,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 19:30:16,,1313220135,7/2/2014 19:29:56,instagc,1,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with LENNOX-GASTAUT SYNDROME,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 21:46:30,,1313404073,7/2/2014 21:46:16,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 22:53:46,,1313453137,7/2/2014 22:53:36,neodev,1,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 23:11:39,,1313465374,7/2/2014 23:09:33,prodege,1,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],SEIZURES associated LENNOX-GASTAUT SYNDROME,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/2/2014 23:20:15,,1313471447,7/2/2014 23:19:58,prodege,1,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187298,7/3/2014 00:30:08,,1313511735,7/3/2014 00:29:36,onestopgpt,1,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,58,83,66,106,-1,RO-has_definitional_manifestation,904874,Management (in combination with other anticonvulsants) of SEIZURES associated with LENNOX-GASTAUT SYNDROME in adults and children ?2 years of age,SEIZURES,LENNOX-GASTAUT SYNDROME
497187299,7/2/2014 14:01:57,,1312964037,7/2/2014 14:01:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 14:55:47,,1312998442,7/2/2014 14:55:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 15:03:41,,1313003089,7/2/2014 15:03:28,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 15:28:20,,1313018176,7/2/2014 15:27:04,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],patients after HERPES ZOSTER and CHICKENPOX,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 16:09:34,,1313043627,7/2/2014 16:09:24,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HERPES ZOSTER CHICKENPOX,n/a,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 18:56:50,,1313188117,7/2/2014 18:56:16,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],convalescent after HERPES ZOSTER and CHICKENPOX,n/a,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 19:21:07,,1313211034,7/2/2014 19:20:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HERPES ZOSTER and CHICKENPOX,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 19:24:44,,1313214656,7/2/2014 19:24:27,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 22:30:27,,1313433308,7/2/2014 22:29:11,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],HERPES ZOSTER and CHICKENPOX,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 22:43:11,,1313441342,7/2/2014 22:43:03,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 23:41:00,,1313486869,7/2/2014 23:40:34,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],treated,n/a,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/2/2014 23:54:56,,1313494983,7/2/2014 23:54:25,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/3/2014 00:45:50,,1313518644,7/3/2014 00:45:03,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HERPES ZOSTER and CHICKENPOX,associated with,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/3/2014 00:52:07,,1313522303,7/3/2014 00:50:32,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],convalescent after and,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187299,7/3/2014 01:23:37,,1313542895,7/3/2014 01:22:55,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[PREVENTS],[PREVENTS],protection,N/A,71,89,84,99,-1,RO-has_causative_agent,903878,"Study of 659 cases treated with serum from patients convalescent after HERPES ZOSTER and CHICKENPOX over a period of two and a half years in French hospital departments, showed the obvious effectiveness of this type of therapy which seems to be better than that of zoster specific gamma globulin used by other workers since we obtained protection against chickenpox in 90 p. cent of cases, and attenuation of chickenpox in 82 p. cent",HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 14:22:34,,1312977276,7/2/2014 14:22:03,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 14:27:29,,1312980499,7/2/2014 14:27:04,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 14:39:48,,1312988827,7/2/2014 14:39:36,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 15:15:23,,1313010337,7/2/2014 15:14:51,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development of CHICKENPOX and/or HERPES ZOSTER,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 15:18:35,,1313012614,7/2/2014 15:18:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development of CHICKENPOX and/or HERPES ZOSTER,n/a,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 16:40:41,,1313064798,7/2/2014 16:39:28,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development of CHICKENPOX and/or HERPES ZOSTER,n/a,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 17:34:25,,1313107823,7/2/2014 17:34:04,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 17:37:46,,1313111287,7/2/2014 17:37:26,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],and/or,dsdssdd,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 19:26:54,,1313216816,7/2/2014 19:26:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHICKENPOX HERPES ZOSTER,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 19:41:40,,1313230802,7/2/2014 19:41:23,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and/or,NA,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 21:49:54,,1313406466,7/2/2014 21:49:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the development of and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 22:14:35,,1313423413,7/2/2014 22:13:41,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],CHICKENPOX and/or HERPES ZOSTER,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 22:37:40,,1313437921,7/2/2014 22:37:19,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[PART_OF],[PART_OF],and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/2/2014 23:35:54,,1313483065,7/2/2014 23:35:26,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/3/2014 00:27:41,,1313510602,7/3/2014 00:25:50,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development of and/or,N/A,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187300,7/3/2014 00:44:03,,1313517794,7/3/2014 00:43:16,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],CHICKENPOX and/or HERPES ZOSTER,is a,164,146,177,156,-1,RO-has_causative_agent,903574,In this article the authors evaluate the immunologic status of acute lymphoblastic leukaemia at diagnosis and at follow up and the development of CHICKENPOX and/or HERPES ZOSTER,HERPES ZOSTER,CHICKENPOX
497187301,7/2/2014 14:07:04,,1312967171,7/2/2014 14:06:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and accelerated the onset of,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 14:28:48,,1312981456,7/2/2014 14:28:33,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[CAUSES],[CAUSES],accelerated onset,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 15:38:09,,1313024155,7/2/2014 15:36:06,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VOMITING and accelerated onset of EMESIS,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 16:23:35,,1313052969,7/2/2014 16:23:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VOMITING EMESIS,n/a,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 17:36:55,,1313110436,7/2/2014 17:36:37,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 19:39:34,,1313228967,7/2/2014 19:39:18,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],onset,NA,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 20:39:50,,1313357609,7/2/2014 20:39:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[CAUSES],[CAUSES],accelerated the onset,N?A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 22:13:40,,1313422925,7/2/2014 22:12:57,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],VOMITING and onset of EMESIS,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 22:49:59,,1313449629,7/2/2014 22:49:49,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 23:01:00,,1313458077,7/2/2014 22:59:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",significantly increased retches VOMITING accelerated onset EMESIS,manifestation and/or causes,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/2/2014 23:49:09,,1313492131,7/2/2014 23:48:47,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],onset,n/a,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/3/2014 00:48:14,,1313520056,7/3/2014 00:48:00,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],accelerated the onset,n/a,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/3/2014 00:52:55,,1313522828,7/3/2014 00:52:11,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],number of accelerated the onset,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/3/2014 00:54:32,,1313523733,7/3/2014 00:53:50,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES],[CAUSES],accelerated,N/A,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187301,7/3/2014 01:50:11,,1313559670,7/3/2014 01:49:32,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],VOMITING and accelerated onset of EMESIS,MANIFESTATION,121,159,129,165,-1,RO-has_definitional_manifestation,904641,"failed to inhibit cisplatin-induced emetic responses and, in contrast, significantly increased the number of retches and VOMITING and accelerated the onset of EMESIS",VOMITING,EMESIS
497187302,7/2/2014 14:36:32,,1312986654,7/2/2014 14:36:19,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE/MIGRAINE,N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 15:36:05,,1313022967,7/2/2014 15:35:38,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],HEADACHE/MIGRAINE,N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 16:26:59,,1313055291,7/2/2014 16:26:48,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE/MIGRAINE,n/a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 16:44:46,,1313067611,7/2/2014 16:44:10,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE/MIGRAINE,n/a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 17:47:25,,1313121859,7/2/2014 17:46:45,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],classifications,dssddssd,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 18:58:03,,1313189453,7/2/2014 18:57:30,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[IS_A],[IS_A],HEADACHE/MIGRAINE,n/a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 19:30:39,,1313220499,7/2/2014 19:30:17,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],HEADACHE/MIGRAINE,N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 19:41:03,,1313230261,7/2/2014 19:40:44,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[IS_A],[IS_A],with,NA,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 19:41:31,,1313230666,7/2/2014 19:41:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],"HEADACHE/MIGRAINE as a residual feature,",N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 20:38:36,,1313356556,7/2/2014 20:38:08,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[PART_OF],[PART_OF],HEADACHE/MIGRAINE,N?A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 22:17:19,,1313425137,7/2/2014 22:16:38,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],patients with HEADACHE/MIGRAINE,N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 22:43:02,,1313441193,7/2/2014 22:42:49,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[IS_A],[IS_A],HEADACHE/MIGRAINE,N/A,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 23:19:27,,1313470829,7/2/2014 23:18:14,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],careful follow-up patients with HEADACHE/MIGRAINE,Is a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/2/2014 23:33:41,,1313481514,7/2/2014 23:33:22,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[MANIFESTATION],[MANIFESTATION],manifestation,n/a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187302,7/3/2014 00:01:15,,1313497898,7/3/2014 00:00:52,neodev,1,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE/MIGRAINE,n/a,284,293,292,301,-1,RO-has_definitional_manifestation,904559,"The potential implications arising from this point of view include (a) a revision of headache/migraine diagnostic criteria as the sole ictal epileptic manifestation in international classifications of both epilepsies and headache disorders; (b) the careful follow-up of patients with HEADACHE/MIGRAINE as a residual feature, taking into consideration a revised concept of &quot;complete seizure control&quot; to avoid mistakes due to inopportune withdrawal of antiepileptic treatment",HEADACHE,MIGRAINE
497187303,7/2/2014 14:56:36,,1312998905,7/2/2014 14:56:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[PART_OF],[PART_OF],"of HERPES ZOSTER (SHINGLES, zoster)",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 15:02:04,,1313002154,7/2/2014 15:01:48,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ZOSTER (SHINGLES, zoster)",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 15:16:06,,1313010783,7/2/2014 15:15:25,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],"HERPES ZOSTER (SHINGLES,",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 15:28:15,,1313018128,7/2/2014 15:28:00,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HERPES ZOSTER (SHINGLES,",n/a,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 17:37:25,,1313110940,7/2/2014 17:37:03,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],of,dssdd,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 19:37:50,,1313227479,7/2/2014 19:37:32,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],of,NA,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 19:41:54,,1313231008,7/2/2014 19:41:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],"HERPES ZOSTER (SHINGLES, zoster)",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 22:29:11,,1313432516,7/2/2014 22:28:29,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],"HERPES ZOSTER (SHINGLES,",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 22:49:31,,1313448727,7/2/2014 22:48:58,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],"HERPES ZOSTER (SHINGLES, zoster)",N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 22:53:36,,1313452999,7/2/2014 22:53:23,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[CAUSES],[CAUSES],history,N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/2/2014 23:46:25,,1313490623,7/2/2014 23:45:51,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/3/2014 00:41:14,,1313516304,7/3/2014 00:40:21,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],"HERPES ZOSTER (SHINGLES,",is a,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/3/2014 00:55:59,,1313524542,7/3/2014 00:54:33,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/3/2014 01:55:57,,1313562629,7/3/2014 01:55:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],"HERPES ZOSTER (SHINGLES, zoster)",PART_OF,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187303,7/3/2014 02:07:45,,1313570020,7/3/2014 02:06:52,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HERPES ZOSTER (SHINGLES,",n/a,425,440,438,448,-1,RO-has_causative_agent,903999,"ACIP states that evidence of varicella immunity includes documentation of age-appropriate vaccination against varicella, laboratory evidence of immunity or laboratory confirmation of prior varicella, birth in the US before 1980 (except pregnant women, immunocompromised individuals, health-care personnel), diagnosis or verification of history of varicella by health-care provider, or diagnosis or verification of history of HERPES ZOSTER (SHINGLES, zoster) by health-care provider",HERPES ZOSTER,SHINGLES
497187304,7/2/2014 14:24:31,,1312978646,7/2/2014 14:23:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",a case of with,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 14:41:06,,1312989633,7/2/2014 14:40:54,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],features,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 15:14:49,,1313009973,7/2/2014 15:13:55,instagc,1.0,21838928,GBR,"","",31.51.188.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SOMATOSTATINOMA with PSAMMOMA BODIES,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 15:19:29,,1313013113,7/2/2014 15:19:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SOMATOSTATINOMA with metastases PSAMMOMA BODIES,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 16:38:30,,1313063263,7/2/2014 16:38:02,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],case of SOMATOSTATINOMA with PSAMMOMA BODIES,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 17:37:59,,1313111487,7/2/2014 17:37:35,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],case with and,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 19:22:28,,1313212430,7/2/2014 19:21:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],SOMATOSTATINOMA with PSAMMOMA BODIES presenting,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 22:15:55,,1313424272,7/2/2014 22:14:35,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",SOMATOSTATINOMA and PSAMMOMA BODIES presenting,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 22:45:09,,1313442686,7/2/2014 22:44:56,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 22:46:49,,1313444083,7/2/2014 22:45:50,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",of with metastases and presenting,N/A,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/2/2014 23:45:02,,1313489616,7/2/2014 23:44:45,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/3/2014 00:43:15,,1313517383,7/3/2014 00:42:26,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],SOMATOSTATINOMA with PSAMMOMA BODIES,part of,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/3/2014 01:43:36,,1313555638,7/3/2014 01:42:54,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],SOMATOSTATINOMA and PSAMMOMA BODIES syndrome neurofibromatosis,symptom,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/3/2014 02:09:58,,1313571403,7/3/2014 02:09:16,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[PART_OF],[PART_OF],SOMATOSTATINOMA PSAMMOMA BODIES,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187304,7/3/2014 02:12:41,,1313573220,7/3/2014 02:12:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],SOMATOSTATINOMA PSAMMOMA BODIES,n/a,56,20,71,35,1,RO-disease_has_finding,901733,We report a case of SOMATOSTATINOMA with metastases and PSAMMOMA BODIES presenting with all three features of the syndrome in a patient with neurofibromatosis,PSAMMOMA BODIES,SOMATOSTATINOMA
497187305,7/2/2014 14:30:54,,1312982906,7/2/2014 14:30:37,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[CAUSES],[CAUSES],is a,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 14:56:56,,1312999112,7/2/2014 14:56:38,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[IS_A],[IS_A],is a,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 15:33:36,,1313021464,7/2/2014 15:33:05,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],MULTICENTRIC RETICULOHISTIOCYTOSIS is a SYSTEMIC DISEASE,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 16:26:01,,1313054647,7/2/2014 16:25:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MULTICENTRIC RETICULOHISTIOCYTOSIS SYSTEMIC DISEASE,n/a,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 17:49:29,,1313124086,7/2/2014 17:48:58,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[TREATS],[TREATS],RETICULOHISTIOCYTOSIS,dsdsdsds,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 17:53:55,,1313128859,7/2/2014 17:53:44,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],RETICULOHISTIOCYTOSIS,dsdsdsds,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 19:36:47,,1313226498,7/2/2014 19:36:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],is a,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 19:43:09,,1313232054,7/2/2014 19:42:54,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[IS_A],[IS_A],is a,NA,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 22:44:55,,1313442539,7/2/2014 22:44:44,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[MANIFESTATION],[MANIFESTATION],is a,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 23:07:05,,1313462276,7/2/2014 23:05:57,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],MULTICENTRIC RETICULOHISTIOCYTOSIS is a SYSTEMIC DISEASE,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 23:21:44,,1313472606,7/2/2014 23:21:34,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],cause,n/a,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/2/2014 23:22:53,,1313473422,7/2/2014 23:21:57,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE,is a,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/3/2014 00:49:22,,1313520755,7/3/2014 00:46:35,prodege,1.0,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],is a,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/3/2014 00:59:22,,1313526602,7/3/2014 00:58:15,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[MANIFESTATION],[MANIFESTATION],is a SYSTEMIC DISEASE,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187305,7/3/2014 01:22:31,,1313542170,7/3/2014 01:21:41,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",characterized,N/A,45,0,61,34,1,RO-disease_has_finding,901779,MULTICENTRIC RETICULOHISTIOCYTOSIS (MR) is a SYSTEMIC DISEASE of unknown cause characterized by the presence of a heavy macrophage infiltrate in skin and synovial tissues and the development of an erosive polyarthritis,SYSTEMIC DISEASE,MULTICENTRIC RETICULOHISTIOCYTOSIS
497187306,7/2/2014 13:45:10,,1312952353,7/2/2014 13:44:36,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[SYMPTOM],[SYMPTOM],symptom,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 14:51:57,,1312996287,7/2/2014 14:51:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A] [SYMPTOM],"[SYMPTOM]
[IS_A]",symptoms,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 15:03:55,,1313003216,7/2/2014 15:03:43,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptom overlap,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 15:08:07,,1313005677,7/2/2014 15:07:06,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],symptom overlap,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 16:27:40,,1313055684,7/2/2014 16:26:47,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],"symptoms in addition to HEADACHE clear symptom overlap among MIGRAINE,",n/a,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 16:28:13,,1313056106,7/2/2014 16:28:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HEADACHE MIGRAINE,",n/a,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 17:41:11,,1313114751,7/2/2014 17:39:28,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptom overlap,n/a,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 19:26:25,,1313216368,7/2/2014 19:26:05,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],among,NA,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 22:11:21,,1313421530,7/2/2014 22:10:20,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],"HEADACHE MIGRAINE,",N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 22:43:41,,1313441688,7/2/2014 22:43:24,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptom overlap,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/2/2014 23:42:10,,1313487720,7/2/2014 23:41:58,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],symptoms,n/a,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/3/2014 00:40:27,,1313515943,7/3/2014 00:39:47,prodege,1.0,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],there is clear symptom overlap,N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/3/2014 00:51:28,,1313521985,7/3/2014 00:51:10,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],symptom overlap among,n/a,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/3/2014 01:04:46,,1313529308,7/3/2014 01:03:16,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]","symptoms in addition to also present, symptom overlap among",N/A,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187306,7/3/2014 01:55:18,,1313562271,7/3/2014 01:54:33,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],"HEADACHE overlap among MIGRAINE,",MANIFESTATION,30,98,38,106,-1,RO-has_definitional_manifestation,904738,"other symptoms in addition to HEADACHE are also present, but there is clear symptom overlap among MIGRAINE, rhinosinusitis, and other nasal passage/sinus pathologic conditions, and further research is needed",HEADACHE,MIGRAINE
497187307,7/2/2014 14:31:56,,1312983606,7/2/2014 14:31:13,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],with an,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 14:42:10,,1312990377,7/2/2014 14:41:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],with an,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 15:18:19,,1313012394,7/2/2014 15:18:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOSIS in a patient with ELEVATED PLATELET COUNT,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 15:25:21,,1313016445,7/2/2014 15:24:26,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SIDE_EFFECT],[SIDE_EFFECT],from SECONDARY THROMBOCYTOSIS with an ELEVATED PLATELET COUNT,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 15:55:46,,1313034943,7/2/2014 15:54:00,clixsense,1,27812714,NLD,06,Tilburg,84.31.160.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],discriminatory significance in the differentiation of a myeloproliferative disorder,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 16:47:46,,1313069707,7/2/2014 16:46:52,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 17:47:40,,1313122130,7/2/2014 17:46:57,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],done,dsdsdsd,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 19:36:51,,1313226555,7/2/2014 19:35:59,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],in a patient with an,NA,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 21:45:23,,1313403339,7/2/2014 21:44:29,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],in a patient with,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 22:21:08,,1313427531,7/2/2014 22:19:36,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],SECONDARY THROMBOCYTOSIS with an ELEVATED PLATELET COUNT,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 22:34:51,,1313436117,7/2/2014 22:34:08,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],with,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 23:37:00,,1313483809,7/2/2014 23:36:34,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],significance differentiation,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/2/2014 23:56:42,,1313495867,7/2/2014 23:55:38,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],patient with an,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/3/2014 00:24:40,,1313509092,7/3/2014 00:23:40,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",with an,N/A,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187307,7/3/2014 00:51:49,,1313522161,7/3/2014 00:51:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],in a patient with an,n/a,206,160,229,184,-1,RO-has_definitional_manifestation,904574,Platelet function tests were done to ascertain whether they might have discriminatory significance in the differentiation of a myeloproliferative disorder from SECONDARY THROMBOCYTOSIS in a patient with an ELEVATED PLATELET COUNT,ELEVATED PLATELET COUNT,SECONDARY THROMBOCYTOSIS
497187308,7/2/2014 14:30:31,,1312982675,7/2/2014 14:30:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[SYMPTOM],[SYMPTOM],PAIN in women suffering from PRIMARY DYSMENORRHEA,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 14:34:19,,1312985221,7/2/2014 14:33:51,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[LOCATION],[LOCATION],suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 14:50:26,,1312995491,7/2/2014 14:50:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",in women suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 15:23:37,,1313015504,7/2/2014 15:23:05,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],PAIN suffering from PRIMARY DYSMENORRHEA,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 16:04:43,,1313040641,7/2/2014 16:04:29,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",PAIN from PRIMARY,n/a,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 16:24:28,,1313053539,7/2/2014 16:23:55,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],PAIN in women suffering from PRIMARY DYSMENORRHEA,n/a,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 17:31:43,,1313105274,7/2/2014 17:31:12,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[SYMPTOM],[SYMPTOM],suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 17:48:25,,1313122970,7/2/2014 17:47:56,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],out,dsdsds,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 18:17:32,,1313150764,7/2/2014 18:16:49,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[SYMPTOM],[SYMPTOM],PAIN in women suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 19:31:45,,1313221644,7/2/2014 19:31:20,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],women suffering from,NA,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 19:32:10,,1313222100,7/2/2014 19:31:33,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],PAIN in women suffering from PRIMARY DYSMENORRHEA,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 22:18:49,,1313426050,7/2/2014 22:17:20,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],PAIN in women suffering PRIMARY DYSMENORRHEA,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 22:47:22,,1313445015,7/2/2014 22:47:08,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[CAUSES],[CAUSES],suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/2/2014 23:25:05,,1313474940,7/2/2014 23:24:50,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],effects,n/a,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187308,7/3/2014 00:32:37,,1313512686,7/3/2014 00:30:17,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[SYMPTOM],[SYMPTOM],suffering from,N/A,172,201,176,221,-1,RO-has_definitional_manifestation,904931,"A double-blind crossover study was carried out to evaluate the therapeutic efficacy of nimesulide and its effects on uterine activity, menstrual fluid prostaglandin F, and PAIN in women suffering from PRIMARY DYSMENORRHEA",PAIN,PRIMARY DYSMENORRHEA
497187309,7/2/2014 14:35:56,,1312986223,7/2/2014 14:35:44,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],in attributed,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 14:42:45,,1312990747,7/2/2014 14:42:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in girls with,n/a,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 14:48:14,,1312994262,7/2/2014 14:47:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],in girls with MCCUNE-ALBRIGHT SYNDROME,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 15:44:41,,1313027953,7/2/2014 15:44:07,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],PRECOCIOUS PUBERTY with MCCUNE-ALBRIGHT SYNDROME,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 16:35:44,,1313061439,7/2/2014 16:35:09,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME,n/a,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 17:36:36,,1313110066,7/2/2014 17:36:07,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in girls with,N/a,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 17:43:59,,1313118186,7/2/2014 17:43:45,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PUBERTY,dsdssdds,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 18:19:12,,1313152331,7/2/2014 18:17:33,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in girls with,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 19:33:02,,1313222891,7/2/2014 19:32:31,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[CAUSES],[CAUSES],in girls with,NA,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 19:41:08,,1313230322,7/2/2014 19:40:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",in girls with,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 22:48:18,,1313446637,7/2/2014 22:48:04,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 23:23:37,,1313473910,7/2/2014 23:22:52,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM] [IS_A],"[SYMPTOM]
[IS_A]",PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/2/2014 23:30:56,,1313479300,7/2/2014 23:30:30,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],attributed,n/a,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/3/2014 00:43:41,,1313517617,7/3/2014 00:43:13,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],in girls with,n/a,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187309,7/3/2014 00:56:51,,1313525048,7/3/2014 00:56:21,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",in girls with has been attributed,N/A,0,33,18,57,1,RO-disease_has_finding,901858,PRECOCIOUS PUBERTY in girls with MCCUNE-ALBRIGHT SYNDROME has been attributed in some cases to early activation of the hypothalamic-pituitary-gonadal axis and in other cases to sex steroid secretion by apparently autonomous ovarian cysts,PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187310,7/2/2014 13:44:35,,1312952003,7/2/2014 13:44:04,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"prevalence of overweight, OBESITY and ABDOMINAL OBESITY",N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 15:03:27,,1313002964,7/2/2014 15:03:16,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 15:50:26,,1313031670,7/2/2014 15:49:53,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],OBESITY and ABDOMINAL OBESITY,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 16:24:19,,1313053462,7/2/2014 16:24:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OBESITY and ABDOMINAL OBESITY,n/a,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 17:39:27,,1313112934,7/2/2014 17:39:08,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],n/a,"list items, not related",75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 17:45:32,,1313119873,7/2/2014 17:45:18,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],between,dsdsdssdds,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 19:20:43,,1313210689,7/2/2014 19:19:24,neodev,1,18963376,GBR,A5,Bedford,92.6.226.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OBESITY and ABDOMINAL OBESITY,na,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 21:48:52,,1313405738,7/2/2014 21:48:11,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],OBESITY,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 22:40:05,,1313439415,7/2/2014 22:39:38,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[MANIFESTATION],[MANIFESTATION],and,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 22:50:11,,1313450012,7/2/2014 22:49:35,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],OBESITY and ABDOMINAL OBESITY,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 23:22:03,,1313472883,7/2/2014 23:21:40,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],OBESITY and ABDOMINAL OBESITY,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/2/2014 23:32:02,,1313480219,7/2/2014 23:31:18,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",rural relationship socio-economic,n/a,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/3/2014 00:46:41,,1313519142,7/3/2014 00:45:52,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],OBESITY and ABDOMINAL OBESITY,is a,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/3/2014 01:22:55,,1313542447,7/3/2014 01:22:32,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationship between,N/A,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187310,7/3/2014 01:49:31,,1313559243,7/3/2014 01:48:58,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],OBESITY and ABDOMINAL OBESITY,PART_OF,75,87,82,104,-1,RO-has_definitional_manifestation,904549,"The objective of the study was evaluation of the prevalence of overweight, OBESITY and ABDOMINAL OBESITY among adult rural population in the Lublin Region, and the relationship between the occurrence of obesity, and selected socio-economic factors",OBESITY,ABDOMINAL OBESITY
497187311,7/2/2014 13:51:48,,1312956913,7/2/2014 13:51:21,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],characterized by,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 14:35:13,,1312985818,7/2/2014 14:35:00,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],characterized by,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 15:17:24,,1313011793,7/2/2014 15:16:56,instagc,1.0,21838928,GBR,"","",31.51.188.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],THROMBOCYTHEMIA characterized by HIGH PLATELET COUNTS,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 15:56:58,,1313035681,7/2/2014 15:54:24,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[SYMPTOM],[SYMPTOM],ESSENTIAL THROMBOCYTHEMIA was characterized by persistently HIGH PLATELET COUNTS,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 16:25:25,,1313054232,7/2/2014 16:25:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ESSENTIAL THROMBOCYTHEMIA HIGH PLATELET COUNTS,n/a,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 16:41:59,,1313065612,7/2/2014 16:41:27,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],ESSENTIAL THROMBOCYTHEMIA was characterized by persistently HIGH PLATELET COUNTS,n/a,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 17:42:22,,1313116185,7/2/2014 17:42:09,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],platelet,dsdsdsds,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 17:53:43,,1313128648,7/2/2014 17:53:30,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],an,dsds,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 19:23:50,,1313213836,7/2/2014 19:22:34,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[SYMPTOM],[SYMPTOM],characterized by persistently,na,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 19:29:09,,1313219060,7/2/2014 19:28:23,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was characterized by persistently,NA,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 19:40:46,,1313229978,7/2/2014 19:40:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",characterized by,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 22:35:55,,1313436917,7/2/2014 22:35:19,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],ESSENTIAL THROMBOCYTHEMIA characterized by HIGH PLATELET COUNTS,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 22:44:06,,1313441968,7/2/2014 22:43:54,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],characterized by persistently,N/A,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 23:24:22,,1313474396,7/2/2014 23:23:33,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",characterized,n/a,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187311,7/2/2014 23:24:38,,1313474564,7/2/2014 23:23:49,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",ESSENTIAL THROMBOCYTHEMIA HIGH PLATELET COUNTS,symptom and/or manifestation,87,0,107,25,1,RO-disease_has_finding,901905,"ESSENTIAL THROMBOCYTHEMIA (ET) in an 11-year-old dog was characterized by persistently HIGH PLATELET COUNTS (range, 4.19 X 10(6)/microliters to 4.95 X 10(6)/microliters, abnormal platelet morphology, marked megakaryocytic hyperplasia in the bone marrow, absence of circulating megakaryoblasts, and history of splenomegaly and gastrointestinal bleeding",HIGH PLATELET COUNTS,ESSENTIAL THROMBOCYTHEMIA
497187312,7/2/2014 13:47:09,,1312953781,7/2/2014 13:46:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[OTHER],[OTHER],various psychiatric diseases including,N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 14:11:47,,1312970217,7/2/2014 14:11:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],various psychiatric diseases including,N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 14:29:01,,1312981638,7/2/2014 14:28:50,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 15:27:59,,1313017970,7/2/2014 15:27:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"COMPULSIVE ANXIETY,",n/a,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 15:35:10,,1313022357,7/2/2014 15:34:34,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]","psychiatric diseases including COMPULSIVE NEUROSIS, ANXIETY,",N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 16:50:02,,1313071512,7/2/2014 16:49:07,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"various psychiatric diseases including COMPULSIVE NEUROSIS, ANXIETY,",n/a,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 17:39:20,,1313112873,7/2/2014 17:38:59,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],mental,dssdsdds,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 19:19:56,,1313209995,7/2/2014 19:18:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],"various psychiatric diseases including COMPULSIVE NEUROSIS, ANXIETY,",Both are psychiatric diseases.,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 19:33:23,,1313223243,7/2/2014 19:33:03,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],including,NA,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 22:39:17,,1313438904,7/2/2014 22:38:06,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 23:18:12,,1313469877,7/2/2014 23:17:05,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"54 cases operated upon various psychiatric diseases COMPULSIVE NEUROSIS, ANXIETY,",associated with,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 23:19:24,,1313470782,7/2/2014 23:18:50,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"including COMPULSIVE NEUROSIS, ANXIETY,",N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/2/2014 23:51:07,,1313493038,7/2/2014 23:50:28,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],including,n/a,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/3/2014 00:01:53,,1313498218,7/3/2014 00:01:16,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,n/a,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187312,7/3/2014 00:46:02,,1313518812,7/3/2014 00:44:44,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",including,N/A,142,109,149,128,-1,RO-has_definitional_manifestation,904505,"The authors report on their experiences in 54 cases operated upon for various psychiatric diseases including COMPULSIVE NEUROSIS, depression, ANXIETY, tension and in some of this group also automutilation; intractable temporal lobe epilepsy and aggressive behaviour; aggressive behaviour and minor epileptic problems; severe mental retardation, restlessness, automultilation and in some of this group also aggression",ANXIETY,COMPULSIVE NEUROSIS
497187313,7/2/2014 14:32:27,,1312983929,7/2/2014 14:32:04,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],considerable value,N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 14:55:19,,1312998163,7/2/2014 14:54:44,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"assessment of ITCH are considerable value for studying PRURITUS,",N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 15:42:28,,1313026709,7/2/2014 15:41:46,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"assessment of ITCH studying mechanisms of PRURITUS,",N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 16:21:45,,1313051838,7/2/2014 16:21:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[SYMPTOM],[SYMPTOM],"ITCH PRURITUS,",n/a,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 16:43:03,,1313066354,7/2/2014 16:42:27,prizerebel,1,16316481,CAN,ON,Toronto,99.244.116.246,[SYMPTOM],[SYMPTOM],considerable value for studying,N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 17:52:26,,1313127324,7/2/2014 17:51:44,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],techniques,dsdssd,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 19:26:04,,1313216015,7/2/2014 19:25:44,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],mechanisms,NA,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 19:43:29,,1313232341,7/2/2014 19:42:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],considerable value for studying the mechanisms of,N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 22:50:12,,1313450015,7/2/2014 22:50:00,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],considerable value,N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 23:15:51,,1313468240,7/2/2014 23:14:45,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],"ITCH for studying the mechanisms PRURITUS,",N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/2/2014 23:25:49,,1313475507,7/2/2014 23:25:06,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],considerable value,n/a,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/3/2014 00:42:01,,1313516735,7/3/2014 00:40:11,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"mechanisms of PRURITUS,",N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/3/2014 00:47:25,,1313519604,7/3/2014 00:46:06,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[SYMPTOM],[SYMPTOM],assessment of,N/A,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/3/2014 01:57:18,,1313563378,7/3/2014 01:55:58,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],"ITCH are value studying PRURITUS,",MANIFESTATION,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187313,7/3/2014 02:12:20,,1313572932,7/3/2014 02:11:13,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],"ITCH are PRURITUS,",n/a,74,136,78,144,-1,RO-has_definitional_manifestation,904862,"This is important, as valid quantitative techniques for the assessment of ITCH are of considerable value for studying the mechanisms of PRURITUS, and for the evaluation of antipruritic therapies",ITCH,PRURITUS
497187314,7/2/2014 14:30:00,,1312982303,7/2/2014 14:29:27,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[OTHER],[OTHER],or,N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 14:38:08,,1312987691,7/2/2014 14:37:53,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 15:16:21,,1313011018,7/2/2014 15:16:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",n/a,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 15:48:17,,1313030280,7/2/2014 15:47:54,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 17:48:57,,1313123581,7/2/2014 17:48:26,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],infectious,dsdsds,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 17:54:31,,1313129567,7/2/2014 17:54:20,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[CONTRAINDICATES] [MANIFESTATION],"[MANIFESTATION]
[CONTRAINDICATES]",respiratory,dsdsds,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 18:16:47,,1313150076,7/2/2014 18:16:03,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 19:11:56,,1313202714,7/2/2014 19:10:42,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[IS_A],[IS_A],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",na,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 19:21:46,,1313211692,7/2/2014 19:21:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 19:38:38,,1313228204,7/2/2014 19:37:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],"or SARS),",N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 19:41:57,,1313231056,7/2/2014 19:41:42,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[IS_A],[IS_A],or,NA,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 22:22:21,,1313428322,7/2/2014 22:21:09,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"(SEVERE ACUTE RESPIRATORY SYNDROME or SARS),",N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 22:51:10,,1313451590,7/2/2014 22:50:33,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/2/2014 23:19:56,,1313471252,7/2/2014 23:19:19,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",include,n/a,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187314,7/3/2014 00:39:55,,1313515764,7/3/2014 00:39:11,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[OTHER] [IS_A],"[IS_A]
[OTHER]",or,N/A,166,129,170,162,-1,RO-has_causative_agent,903935,"Occupational pulmonary infectious diseases include tuberculosis (TB) and many viral pathogens, including influenza, coronavirus (SEVERE ACUTE RESPIRATORY SYNDROME or SARS), varicella, respiratory syncytial virus, and hantavirus",SARS,SEVERE ACUTE RESPIRATORY SYNDROME
497187315,7/2/2014 14:40:53,,1312989517,7/2/2014 14:40:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],considering the patients' sensation,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 15:51:45,,1313032444,7/2/2014 15:50:28,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",PRURITUS considering sensation of ITCH,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 16:05:55,,1313041369,7/2/2014 16:05:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[SIDE_EFFECT],[SIDE_EFFECT],PRURITUS ITCH,n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 16:28:58,,1313056680,7/2/2014 16:27:40,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],"PRURITUS in patients with atopic dermatitis, considering patients' sensation of ITCH",n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 17:47:55,,1313122435,7/2/2014 17:47:26,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],assess,dsdsdsds,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 21:46:56,,1313404363,7/2/2014 21:46:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],patients' sensation of,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 22:52:48,,1313452537,7/2/2014 22:52:39,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[MANIFESTATION],[MANIFESTATION],of,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 23:28:31,,1313477379,7/2/2014 23:27:20,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],PRURITUS considering patients' sensation of ITCH,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/2/2014 23:32:48,,1313480826,7/2/2014 23:32:24,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 00:25:45,,1313509579,7/3/2014 00:24:44,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",considering the patients' sensation,N/A,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 00:47:39,,1313519714,7/3/2014 00:46:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],considering the patients' sensation,n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 01:48:34,,1313558722,7/3/2014 01:47:46,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],PRURITUS sensation of ITCH,SYMPTOM,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 02:06:49,,1313569318,7/3/2014 02:06:01,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],PRURITUS ITCH,n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 02:10:57,,1313572116,7/3/2014 02:10:25,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],PRURITUS ITCH,n/a,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187315,7/3/2014 03:01:04,,1313600744,7/3/2014 03:00:41,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,[CAUSES],[CAUSES],PRURITUS,NONE,77,161,85,165,-1,RO-has_definitional_manifestation,904699,"The aim of the study was to assess the therapeutic efficacy of loratadine on PRURITUS in patients with atopic dermatitis, considering the patients' sensation of ITCH",PRURITUS,ITCH
497187316,7/2/2014 14:31:13,,1312983097,7/2/2014 14:30:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],criteria,N/A,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 14:42:22,,1312990500,7/2/2014 14:42:12,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 15:18:13,,1313012333,7/2/2014 15:17:25,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Falciparum malaria: symptoms,N/A,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 16:08:00,,1313042605,7/2/2014 16:07:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUCOPENIA; PANCYTOPENIA,",n/a,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 16:48:22,,1313070222,7/2/2014 16:47:48,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"criteria for differential diagnosis LEUCOPENIA; PANCYTOPENIA,",n/a,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 17:38:31,,1313112007,7/2/2014 17:38:08,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CAUSES],[CAUSES],echinococcosis:,dssddsd,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 18:23:40,,1313156267,7/2/2014 18:21:49,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[NONE],[NONE],n/a,The sentence is referring to separate case studies of separate medical conditions,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 19:18:43,,1313208840,7/2/2014 19:17:19,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[NONE],[NONE],na,no evidence that any relations are applicable,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 19:35:10,,1313224910,7/2/2014 19:34:45,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],with,NA,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 19:37:54,,1313227537,7/2/2014 19:36:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],case histories:,N/A,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 22:50:22,,1313450288,7/2/2014 22:50:13,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],insidious course,N/A,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 23:02:52,,1313459417,7/2/2014 23:01:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],"LEUCOPENIA; PANCYTOPENIA, symptoms of a benign tumor",symptoms,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 23:26:18,,1313475800,7/2/2014 23:25:46,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"LEUCOPENIA; PANCYTOPENIA,",N/A,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/2/2014 23:28:26,,1313477363,7/2/2014 23:25:51,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],symptoms,n/a,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187316,7/3/2014 00:04:12,,1313499418,7/3/2014 00:02:58,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],presented with reference case histories:,n/a,178,230,188,242,-1,RO-has_definitional_manifestation,904745,"The most important criteria for differential diagnosis are presented with reference to case histories: Falciparum malaria: relapsing fever, hemolytic anemia, hepatosplenomegaly, LEUCOPENIA; Kala-azar: insidious course with fever, PANCYTOPENIA, macrocytic anemia, hepatosplenomegaly, enlargement of lymph nodes; echinococcosis: symptoms of a benign tumor with displacement",LEUCOPENIA,PANCYTOPENIA
497187317,7/2/2014 14:02:28,,1312964409,7/2/2014 14:02:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],(MIGRAINE or of straining type),N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 14:28:31,,1312981254,7/2/2014 14:26:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE--primary,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 14:54:43,,1312997814,7/2/2014 14:54:14,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE--primary (MIGRAINE,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 15:23:04,,1313015218,7/2/2014 15:22:33,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],HEADACHE--primary (MIGRAINE,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 16:26:13,,1313054764,7/2/2014 16:26:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE--primary (MIGRAINE,n/a,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 16:45:42,,1313068278,7/2/2014 16:45:20,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],HEADACHE--primary (MIGRAINE,n/a,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 17:42:51,,1313116905,7/2/2014 17:42:27,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[IS_A],[IS_A],expressed as,n/a,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 18:24:12,,1313156667,7/2/2014 18:23:40,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[IS_A],[IS_A],HEADACHE--primary (MIGRAINE,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 22:49:13,,1313448242,7/2/2014 22:49:04,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 23:18:49,,1313470289,7/2/2014 23:18:17,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],expressed as HEADACHE--primary (MIGRAINE,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/2/2014 23:29:01,,1313477792,7/2/2014 23:28:50,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],(symptom,n/a,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/3/2014 00:54:16,,1313523623,7/3/2014 00:52:59,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],or of straining type) and,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/3/2014 01:20:48,,1313541062,7/3/2014 01:20:12,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]",definite,N/A,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/3/2014 01:58:18,,1313563935,7/3/2014 01:57:51,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE--primary (MIGRAINE or of straining type),ASSOCIATED_WITH,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187317,7/3/2014 02:08:28,,1313570543,7/3/2014 02:07:49,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE--primary (MIGRAINE,n/a,30,49,38,57,-1,RO-has_definitional_manifestation,904536,Clinically it is expressed as HEADACHE--primary (MIGRAINE or of straining type) and secondary (symptom of a definite illness,HEADACHE,MIGRAINE
497187318,7/2/2014 13:49:17,,1312955141,7/2/2014 13:48:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOPENIA and GRANULOCYTOPENIA in the latter,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 14:31:46,,1312983491,7/2/2014 14:31:33,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 14:49:31,,1312995003,7/2/2014 14:48:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and in,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 15:26:20,,1313017012,7/2/2014 15:25:23,instagc,1.0,21838928,GBR,"","",31.51.188.207,[NONE],[NONE],N/A,"There does not seem to be any relation, as there's no information about any relation that might exist.",4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 16:29:34,,1313057112,7/2/2014 16:29:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",LEUKOPENIA and GRANULOCYTOPENIA,n/a,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 16:32:08,,1313059066,7/2/2014 16:31:34,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOPENIA and GRANULOCYTOPENIA is much less pronounced,n/a,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 17:12:22,,1313089115,7/2/2014 17:10:51,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[OTHER],[OTHER],The LEUKOPENIA and GRANULOCYTOPENIA,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 17:41:53,,1313115526,7/2/2014 17:41:40,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],GRANULOCYTOPENIA,dsdssdds,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 19:42:13,,1313231235,7/2/2014 19:41:59,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 22:41:12,,1313440130,7/2/2014 22:40:25,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 23:21:39,,1313472542,7/2/2014 23:20:28,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],LEUKOPENIA and GRANULOCYTOPENIA,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/2/2014 23:47:09,,1313491013,7/2/2014 23:46:26,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],and,n/a,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/3/2014 00:02:56,,1313498683,7/3/2014 00:02:42,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/3/2014 00:33:16,,1313512982,7/3/2014 00:32:41,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187318,7/3/2014 00:48:33,,1313520225,7/3/2014 00:48:15,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,4,19,14,35,-1,RO-has_definitional_manifestation,904772,The LEUKOPENIA and GRANULOCYTOPENIA in the latter is much less pronounced and probably reflects the phenomenon &quot;frustrated phagocytosis,LEUKOPENIA,GRANULOCYTOPENIA
497187319,7/2/2014 14:05:01,,1312965917,7/2/2014 14:04:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],separated into,N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 14:39:07,,1312988268,7/2/2014 14:38:41,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 15:27:02,,1313017437,7/2/2014 15:26:21,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER] [PART_OF],"[PART_OF]
[OTHER]","diagnoses separated into EPILEPSY PSEUDOSEIZURES,",N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 16:24:45,,1313053721,7/2/2014 16:24:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"EPILEPSY alone, PSEUDOSEIZURES,",n/a,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 16:36:18,,1313061827,7/2/2014 16:35:45,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Final diagnoses were separated into PSEUDOSEIZURES, epilepsy",n/a,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 17:40:24,,1313113921,7/2/2014 17:40:05,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SIDE_EFFECT],[SIDE_EFFECT],diagnoses,dsdsdssd,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 17:41:29,,1313115059,7/2/2014 17:41:12,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],separated into,n/a,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 19:30:43,,1313220616,7/2/2014 19:30:23,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],"alone,",NA,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 22:45:36,,1313443008,7/2/2014 22:45:26,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],separated into,N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 23:13:44,,1313466684,7/2/2014 23:13:15,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],"EPILEPSY alone, PSEUDOSEIZURES,",N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/2/2014 23:45:25,,1313489955,7/2/2014 23:45:17,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnoses,n/a,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/3/2014 00:40:09,,1313515834,7/3/2014 00:38:32,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and other,N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/3/2014 00:44:25,,1313518024,7/3/2014 00:43:46,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/3/2014 01:27:55,,1313545406,7/3/2014 01:25:56,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"separated into EPILEPSY alone, PSEUDOSEIZURES,",N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187319,7/3/2014 01:29:41,,1313546503,7/3/2014 01:27:56,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were separated into,N/A,52,36,66,44,-1,RO-has_definitional_manifestation,904832,"Final diagnoses were separated into EPILEPSY alone, PSEUDOSEIZURES, epilepsy and pseudoseizures, and other (neither epilepsy nor pseudoseizures",PSEUDOSEIZURES,EPILEPSY
497187320,7/2/2014 14:38:22,,1312987864,7/2/2014 14:38:09,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],significantly fewer occurrences,N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 15:53:48,,1313033669,7/2/2014 15:53:20,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SIDE_EFFECT],[SIDE_EFFECT],"INFECTIOUS MONONUCLEOSIS fewer occurrences of LYMPHADENOPATHY,",N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 16:07:47,,1313042472,7/2/2014 16:07:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"had significantly fewer pharyngitis,",n/a,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 16:46:51,,1313069050,7/2/2014 16:46:22,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],"elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of LYMPHADENOPATHY,",n/a,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 17:51:05,,1313125818,7/2/2014 17:50:35,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],MONONUCLEOSIS,dsdssdds,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 17:54:19,,1313129333,7/2/2014 17:54:09,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],MONONUCLEOSIS,dsdsdsdsds,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 18:15:09,,1313148507,7/2/2014 18:13:51,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[SYMPTOM],[SYMPTOM],fewer occurrences of,N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 19:37:31,,1313227227,7/2/2014 19:37:10,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],The elderly with,NA,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 19:40:17,,1313229532,7/2/2014 19:39:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",occurrences of,N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 22:48:36,,1313447129,7/2/2014 22:48:27,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 23:08:11,,1313462978,7/2/2014 23:07:07,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],"INFECTIOUS MONONUCLEOSIS fewer occurrences LYMPHADENOPATHY,",N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 23:11:25,,1313465242,7/2/2014 23:09:38,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],"elderly INFECTIOUS MONONUCLEOSIS fewer occurrences pharyngitis, LYMPHADENOPATHY,",manifestation,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/2/2014 23:50:25,,1313492724,7/2/2014 23:49:11,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,n/a,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/3/2014 00:45:15,,1313518380,7/3/2014 00:44:57,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],significantly fewer occurrences of,n/a,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187320,7/3/2014 00:50:28,,1313521387,7/3/2014 00:49:43,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[LOCATION] [SYMPTOM],"[LOCATION]
[SYMPTOM]",occurrences of,N/A,94,17,109,41,1,RO-disease_has_finding,901833,"The elderly with INFECTIOUS MONONUCLEOSIS had significantly fewer occurrences of pharyngitis, LYMPHADENOPATHY, and splenomegaly when compared with young adults",LYMPHADENOPATHY,INFECTIOUS MONONUCLEOSIS
497187321,7/2/2014 14:31:32,,1312983318,7/2/2014 14:31:16,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],recorded intracranially during,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 15:49:50,,1313031271,7/2/2014 15:49:17,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",TEMPORAL LOBE EPILEPSY recorded SEIZURE,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 16:08:39,,1313042971,7/2/2014 16:08:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TEMPORAL EPILEPSY SEIZURE,n/a,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 16:43:04,,1313066347,7/2/2014 16:42:32,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],patients with TEMPORAL LOBE EPILEPSY during transitions to SEIZURE,n/a,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 17:39:43,,1313113247,7/2/2014 17:39:21,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CAUSES],[CAUSES],method,dssdds,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 17:53:07,,1313127949,7/2/2014 17:52:50,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],method,dsdsdsds,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 19:27:52,,1313217787,7/2/2014 19:26:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study of TEMPORAL LOBE EPILEPSY recorded during SEIZURE,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 19:29:37,,1313219469,7/2/2014 19:29:12,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],recorded intracranially during transitions,NA,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 19:31:50,,1313221738,7/2/2014 19:31:01,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",patients with during transitions to,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 22:34:09,,1313435764,7/2/2014 22:33:11,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],TEMPORAL LOBE EPILEPSY to SEIZURE,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 22:43:23,,1313441506,7/2/2014 22:43:12,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],transitions to,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 23:12:44,,1313466045,7/2/2014 23:11:27,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],TEMPORAL LOBE EPILEPSY during transitions SEIZURE,manifestation,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/2/2014 23:37:47,,1313484467,7/2/2014 23:37:02,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",intracranially,n/a,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/3/2014 00:43:40,,1313517615,7/3/2014 00:43:13,prodege,1.0,2145087,USA,"","",184.53.6.188,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",during transitions to,N/A,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187321,7/3/2014 00:45:43,,1313518553,7/3/2014 00:45:17,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],recorded intracranially during transitions,n/a,131,62,138,84,-1,RO-has_definitional_manifestation,904604,We apply this method to the study of a group of patients with TEMPORAL LOBE EPILEPSY recorded intracranially during transitions to SEIZURE,SEIZURE,TEMPORAL LOBE EPILEPSY
497187322,7/2/2014 14:30:20,,1312982492,7/2/2014 14:30:07,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],appeared,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 14:56:08,,1312998665,7/2/2014 14:55:48,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[SYMPTOM],[SYMPTOM],patient was diagnosed as,M/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 15:20:45,,1313013876,7/2/2014 15:20:16,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],FEVER diagnosed MULTICENTRIC CASTLEMAN'S DISEASE,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 16:22:01,,1313051989,7/2/2014 16:21:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FEVER MULTICENTRIC CASTLEMAN'S DISEASE,n/a,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 17:37:17,,1313110777,7/2/2014 17:36:55,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[SYMPTOM],[SYMPTOM],appeared diagnosed as,n/a,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 19:10:40,,1313201602,7/2/2014 19:09:39,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[SYMPTOM],[SYMPTOM],FEVER appeared diagnosed MULTICENTRIC CASTLEMAN'S DISEASE,na,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 19:27:36,,1313217554,7/2/2014 19:27:11,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],appeared patient was diagnosed,NA,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 19:34:45,,1313224508,7/2/2014 19:34:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",appeared diagnosed as,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 22:48:26,,1313446868,7/2/2014 22:48:18,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosed as,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 23:21:08,,1313472201,7/2/2014 23:20:37,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],diagnosed,n/a,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/2/2014 23:25:45,,1313475431,7/2/2014 23:25:15,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],FEVER appeared and was diagnosed MULTICENTRIC CASTLEMAN'S DISEASE,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/3/2014 00:00:03,,1313497231,7/2/2014 23:59:31,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],appeared diagnosed,n/a,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/3/2014 00:49:25,,1313520780,7/3/2014 00:48:24,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],FEVER appeared patient diagnosed MULTICENTRIC CASTLEMAN'S DISEASE,symptom,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/3/2014 01:03:02,,1313528582,7/3/2014 01:01:58,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",was diagnosed as,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187322,7/3/2014 01:18:31,,1313539384,7/3/2014 01:17:46,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",FEVER diagnosed,N/A,32,80,37,112,1,RO-disease_has_finding,901863,Generalized lymphadenopathy and FEVER appeared and the patient was diagnosed as MULTICENTRIC CASTLEMAN'S DISEASE (MCD) at 40 years of age,FEVER,MULTICENTRIC CASTLEMAN'S DISEASE
497187323,7/2/2014 14:32:44,,1312984168,7/2/2014 14:32:28,fepcrowdflower,1,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],accompanying signs,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 15:47:19,,1313029587,7/2/2014 15:46:28,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],PAIN NEUROPATHIC PAIN,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 16:08:12,,1313042699,7/2/2014 16:08:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PAIN NEUROPATHIC PAIN,n/a,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 17:43:12,,1313117224,7/2/2014 17:42:52,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[SYMPTOM],[SYMPTOM],presenting with,n/a,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 17:48:09,,1313122649,7/2/2014 17:47:41,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[CAUSES],[CAUSES],therapeutic,sdsdsdssd,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 18:13:50,,1313147375,7/2/2014 18:12:28,prodege,1,9378607,GBR,U8,Edinburgh,94.1.221.80,[IS_A],[IS_A],patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 19:32:37,,1313222495,7/2/2014 19:31:52,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],presenting with furthered our ability to define,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 19:37:09,,1313226827,7/2/2014 19:36:53,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 22:47:07,,1313444562,7/2/2014 22:46:19,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],define,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 23:13:14,,1313466367,7/2/2014 23:11:40,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],PAIN our ability to define NEUROPATHIC PAIN,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/2/2014 23:33:56,,1313481659,7/2/2014 23:33:43,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],symptoms,n/a,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/3/2014 00:23:35,,1313508638,7/3/2014 00:22:56,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],furthered our ability to define,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/3/2014 00:44:56,,1313518207,7/3/2014 00:44:36,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],has furthered our ability define,n/a,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/3/2014 00:53:48,,1313523306,7/3/2014 00:53:03,clixsense,1,10428985,GBR,M3,South Petherton,86.186.150.111,[SYMPTOM],[SYMPTOM],signs and symptoms,N/A,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187323,7/3/2014 01:44:15,,1313556062,7/3/2014 01:43:37,instagc,1,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],PAIN furthered define NEUROPATHIC PAIN,PART__OF,64,105,68,121,-1,RO-has_definitional_manifestation,904677,Consensus on evaluation strategies for patients presenting with PAIN has furthered our ability to define NEUROPATHIC PAIN and accompanying signs and symptoms that may respond to particular therapeutic approaches,PAIN,NEUROPATHIC PAIN
497187324,7/2/2014 14:39:21,,1312988468,7/2/2014 14:39:08,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 14:52:35,,1312996613,7/2/2014 14:51:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHE;,N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 15:09:50,,1313006704,7/2/2014 15:08:09,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],diagnoses,N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 16:23:48,,1313053099,7/2/2014 16:23:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE; TENSION HEADACHE) ED,n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 16:50:32,,1313071947,7/2/2014 16:50:03,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],discharge diagnoses HEADACHE; and TENSION HEADACHE),n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 22:43:53,,1313441821,7/2/2014 22:43:42,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 23:14:45,,1313467395,7/2/2014 23:14:11,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[TREATS] [IS_A],"[TREATS]
[IS_A]",HEADACHE; and TENSION HEADACHE),N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 23:23:48,,1313474062,7/2/2014 23:22:54,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],HEADACHE; and TENSION HEADACHE),is a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/2/2014 23:38:50,,1313485190,7/2/2014 23:38:27,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnoses,n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 00:50:43,,1313521569,7/3/2014 00:49:52,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],and,n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 00:51:31,,1313521998,7/3/2014 00:49:24,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"""inappropriate""",N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 01:33:00,,1313548707,7/3/2014 01:32:23,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],HEADACHE; and TENSION HEADACHE),N/A,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 01:58:50,,1313564300,7/3/2014 01:58:19,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],HEADACHE; and TENSION HEADACHE),SYMPTOM,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 02:09:44,,1313571258,7/3/2014 02:08:24,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE; TENSION HEADACHE),n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187324,7/3/2014 02:11:10,,1313572256,7/3/2014 02:10:37,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE; TENSION HEADACHE),n/a,199,213,207,229,-1,RO-has_definitional_manifestation,904815,"In this retrospective database review, 11 discharge diagnoses (DX11) (chronic nasopharyngitis; chronic sinusitis; chronic pharyngitis; rhinitis; constipation; head cold; hemorrhoids; toothache; flu; HEADACHE; and TENSION HEADACHE) were identified by a third party payor as being &quot;inappropriate&quot; for ED evaluation",HEADACHE,TENSION HEADACHE
497187325,7/2/2014 14:34:59,,1312985696,7/2/2014 14:34:40,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and any,N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 14:51:15,,1312995965,7/2/2014 14:50:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and any,N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 15:13:54,,1313009360,7/2/2014 15:12:46,instagc,1.0,21838928,GBR,"","",31.51.188.207,[CAUSES],[CAUSES],"binge eating disorder, BINGE EATING EDs",N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 16:12:12,,1313045333,7/2/2014 16:10:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]","BINGE EATING DISORDER, BINGE EATING",n/a,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 16:21:16,,1313051574,7/2/2014 16:20:25,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],"BINGE EATING DISORDER, and any BINGE EATING",n/a,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 17:37:02,,1313110548,7/2/2014 17:36:37,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CAUSES],[CAUSES],"respectively,",dssdsdds,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 17:42:13,,1313115911,7/2/2014 17:41:29,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],higher among women all,n/a,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 19:31:18,,1313221201,7/2/2014 19:30:45,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],and any,NA,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 22:16:37,,1313424742,7/2/2014 22:15:56,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],"BINGE EATING DISORDER, and BINGE EATING",N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 22:53:09,,1313452750,7/2/2014 22:52:57,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 23:09:36,,1313464012,7/2/2014 23:07:22,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"BINGE EATING DISORDER, any BINGE EATING",associated with,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/2/2014 23:23:31,,1313473871,7/2/2014 23:22:21,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SIDE_EFFECT] [CAUSES],"[CAUSES]
[SIDE_EFFECT]",estimated higher,n/a,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/3/2014 00:45:36,,1313518512,7/3/2014 00:44:34,prodege,1.0,2145087,USA,"","",184.53.6.188,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",and,N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/3/2014 00:49:22,,1313520760,7/3/2014 00:48:00,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES],[CAUSES],were 3-8 times higher,N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187325,7/3/2014 00:49:38,,1313520882,7/3/2014 00:47:29,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],"prevalence of BINGE EATING DISORDER, and any BINGE EATING",N/A,136,68,148,89,-1,RO-has_definitional_manifestation,904670,"Lifetime estimated prevalence of anorexia nervosa, bulimia nervosa, BINGE EATING DISORDER, sub-threshold binge eating disorder, and any BINGE EATING were 0.48%, 0.51%, 1.12%, 0.72%, and 2.15%, respectively, and they were 3-8 times higher among women for all EDs",BINGE EATING,BINGE EATING DISORDER
497187326,7/2/2014 13:47:28,,1312953957,7/2/2014 13:47:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],manifest itself,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 14:44:29,,1312991882,7/2/2014 14:42:47,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],does not manifest,n/a,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 15:01:47,,1313001990,7/2/2014 15:01:34,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],form of,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 15:07:05,,1313004990,7/2/2014 15:06:15,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],form of,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 16:26:05,,1313054688,7/2/2014 16:25:23,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],MIGRAINE manifest itself in the form of HEADACHE,n/a,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 17:30:32,,1313104121,7/2/2014 17:29:58,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[MANIFESTATION],[MANIFESTATION],manifest,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 17:49:42,,1313124334,7/2/2014 17:49:12,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],manifest,dsdsdsds,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 19:38:11,,1313227760,7/2/2014 19:37:51,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],in the form of,NA,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 21:50:10,,1313406615,7/2/2014 21:49:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],manifest itself in the form of,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 22:52:29,,1313452334,7/2/2014 22:51:11,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 23:19:56,,1313471269,7/2/2014 23:19:25,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],MIGRAINE manifest in the form of HEADACHE,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/2/2014 23:45:16,,1313489800,7/2/2014 23:45:03,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[MANIFESTATION],[MANIFESTATION],manifest,n/a,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/3/2014 00:46:04,,1313518814,7/3/2014 00:45:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],does not manifest itself in the form of,n/a,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/3/2014 00:56:56,,1313525132,7/3/2014 00:56:00,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[MANIFESTATION],[MANIFESTATION],manifest,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187326,7/3/2014 01:34:26,,1313549802,7/3/2014 01:33:49,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [MANIFESTATION],"[MANIFESTATION]
[IS_A]",in the form of,N/A,52,3,60,11,-1,RO-has_definitional_manifestation,904844,"If MIGRAINE does not manifest itself in the form of HEADACHE but in some other form such as paroxysmal episodes of prolonged visual auras, atypical sensory, motor, or visual aura, confusion, dysarthria, focal neurologic deficits with or without a headache, it is labelled a Migraine Variant (MV",HEADACHE,MIGRAINE
497187327,7/2/2014 15:02:38,,1313002450,7/2/2014 15:02:22,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],types of,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 15:24:24,,1313015949,7/2/2014 15:23:39,instagc,1.0,21838928,GBR,"","",31.51.188.207,[PART_OF] [OTHER],"[PART_OF]
[OTHER]",types of SEIZURE,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 16:10:41,,1313044396,7/2/2014 16:10:08,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURE PETIT MAL,n/a,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 17:31:10,,1313104817,7/2/2014 17:30:37,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[CAUSES],[CAUSES],awakening,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 19:32:30,,1313222393,7/2/2014 19:32:09,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],was awakening,NA,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 19:36:20,,1313225996,7/2/2014 19:35:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],types of,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 22:30:58,,1313433696,7/2/2014 22:30:29,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],SEIZURE or PETIT MAL,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 22:37:18,,1313437690,7/2/2014 22:36:39,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[NONE],[NONE],N/A,Petite mal are a type of seizure,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/2/2014 23:40:33,,1313486500,7/2/2014 23:40:08,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[MANIFESTATION],[MANIFESTATION],Distribution awakening,n/a,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 00:19:43,,1313506807,7/3/2014 00:18:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],types of SEIZURE PETIT MAL,is a,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 00:39:06,,1313515436,7/3/2014 00:38:23,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",absence or myoclonic,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 00:51:09,,1313521853,7/3/2014 00:50:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],absence or myoclonic,n/a,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 01:27:36,,1313545197,7/3/2014 01:26:58,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],types of SEIZURE,N/A,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 01:47:45,,1313558243,7/3/2014 01:46:51,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],SEIZURE awakening PETIT MAL,symptom,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187327,7/3/2014 02:06:29,,1313569142,7/3/2014 02:05:20,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],SEIZURE PETIT MAL,n/a,25,79,32,88,-1,RO-has_definitional_manifestation,904762,"Distribution by types of SEIZURE was awakening grand mal, absence or myoclonic PETIT MAL in 24%, grand mal with no aura in 21%, grand mal during sleep in 23%, diffuse grand mal in 7%, grand mal with aura in 13%, psychomotor seizure in 9%, and focal seizure in 3%",SEIZURE,PETIT MAL
497187328,7/2/2014 13:48:21,,1312954551,7/2/2014 13:47:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had previously been classified as,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 14:32:04,,1312983666,7/2/2014 14:31:48,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[OTHER],[OTHER],classified,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 15:41:45,,1313026236,7/2/2014 15:41:11,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],patients with MIGRAINE as having HEADACHE,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 16:10:07,,1313044089,7/2/2014 16:09:48,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHE,n/aa,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 16:49:06,,1313070845,7/2/2014 16:48:23,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[IS_A],[IS_A],patients with MIGRAINE been classified as having HEADACHE,n/a,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 17:44:59,,1313119297,7/2/2014 17:44:45,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],previously,dsdssdsd,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 17:52:48,,1313127653,7/2/2014 17:52:02,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],previously,dsdsdsdsds,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 19:26:50,,1313216784,7/2/2014 19:26:27,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],with,NA,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 21:46:14,,1313403901,7/2/2014 21:45:45,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],not otherwise specified;,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 22:35:36,,1313436684,7/2/2014 22:34:51,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[NONE],[NONE],N/A,Headaches are similar to migraines,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 23:07:21,,1313462449,7/2/2014 23:05:43,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],MIGRAINE HEADACHE,is a,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 23:17:49,,1313469604,7/2/2014 23:17:05,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],MIGRAINE and HEADACHE,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/2/2014 23:29:35,,1313478222,7/2/2014 23:29:03,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],application,n/a,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/3/2014 00:42:02,,1313516748,7/3/2014 00:41:27,prodege,1.0,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],had previously been classified as having,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187328,7/3/2014 01:01:54,,1313528025,7/3/2014 01:01:23,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [SYMPTOM],"[SYMPTOM]
[IS_A]",previously been classified as having,N/A,217,137,225,145,-1,RO-has_definitional_manifestation,904503,"After retrospective application of the IHS classification, the diagnostic distribution was modified, revealing that 18% of patients with MIGRAINE and 5% with cluster headaches had previously been classified as having HEADACHE not otherwise specified; a further 6% of cases with migraine and 0.4% of patients with cluster headache had previously been classified as having secondary headaches",HEADACHE,MIGRAINE
497187329,7/2/2014 14:40:25,,1312989233,7/2/2014 14:39:50,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 14:44:59,,1312992211,7/2/2014 14:44:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"VOMITING, and HEMATEMESIS",n/a,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 15:34:32,,1313022003,7/2/2014 15:34:11,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"VOMITING, and HEMATEMESIS",N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 17:14:49,,1313091027,7/2/2014 17:12:23,neodev,1,20929875,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"tumor man presented with abdominal pain, VOMITING, and HEMATEMESIS",N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 17:37:34,,1313111117,7/2/2014 17:37:18,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],n/a,"list items, not related",108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 17:40:44,,1313114234,7/2/2014 17:40:25,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],additional,dssdsdd,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 18:19:41,,1313152800,7/2/2014 18:19:13,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"presented with abdominal pain, VOMITING, and HEMATEMESIS",N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 19:29:55,,1313219756,7/2/2014 19:29:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],"presented with VOMITING, HEMATEMESIS",Both are symptoms.,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 19:34:15,,1313224030,7/2/2014 19:33:48,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],with and,NA,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 19:35:07,,1313224838,7/2/2014 19:34:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 22:48:44,,1313447392,7/2/2014 22:48:37,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[CAUSES],[CAUSES],and,N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 23:28:48,,1313477653,7/2/2014 23:28:28,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],presented,n/a,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/2/2014 23:30:01,,1313478566,7/2/2014 23:28:31,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"VOMITING, and HEMATEMESIS",N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/3/2014 00:42:25,,1313516919,7/3/2014 00:41:16,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],"VOMITING, HEMATEMESIS",symptom,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187329,7/3/2014 00:56:17,,1313524756,7/3/2014 00:55:39,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",presented with and,N/A,108,122,116,133,-1,RO-has_definitional_manifestation,904649,"Here we report an additional case of this tumor in a Chinese 78-year-old man presented with abdominal pain, VOMITING, and HEMATEMESIS",VOMITING,HEMATEMESIS
497187330,7/2/2014 14:41:41,,1312989985,7/2/2014 14:41:21,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 15:16:54,,1313011410,7/2/2014 15:16:08,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],VZV-specific DNA demonstrated in patients with VARICELLA patients with ZOSTER,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 16:08:26,,1313042841,7/2/2014 16:08:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VARICELLA ZOSTER,n/a,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 17:40:04,,1313113580,7/2/2014 17:39:45,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],ZOSTER,dsdsdsds,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 21:48:09,,1313405176,7/2/2014 21:46:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,Two different things.,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 22:31:48,,1313434318,7/2/2014 22:30:58,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],VARICELLA ZOSTER,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 22:48:47,,1313447476,7/2/2014 22:47:43,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[OTHER],[OTHER],patients with and in one with disseminated zoster out of five patients with,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 22:52:56,,1313452601,7/2/2014 22:52:49,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/2/2014 23:21:32,,1313472461,7/2/2014 23:21:10,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],demonstrated,n/a,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 00:00:51,,1313497660,7/3/2014 00:00:04,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],demonstrated,n/a,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 00:37:34,,1313514857,7/3/2014 00:36:42,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 01:19:29,,1313540030,7/3/2014 01:18:33,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",demonstrated,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 01:33:27,,1313549095,7/3/2014 01:30:40,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[MANIFESTATION],[MANIFESTATION],VZV-specific DNA was demonstrated in nine patients with VARICELLA and one with ZOSTER,N/A,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 01:52:42,,1313561003,7/3/2014 01:51:55,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],VZV-specific DNA demonstrated in VARICELLA and ZOSTER,SYMPTOM,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187330,7/3/2014 02:13:31,,1313573645,7/3/2014 02:12:46,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],VARICELLA ZOSTER,n/a,86,158,95,164,-1,RO-has_causative_agent,903686,VZV-specific DNA was demonstrated in 15 lymphocyte preparations of nine patients with VARICELLA and in one with disseminated zoster out of five patients with ZOSTER,VARICELLA,ZOSTER
497187331,7/2/2014 13:47:51,,1312954259,7/2/2014 13:47:29,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[SYMPTOM],[SYMPTOM],clinical signs that were consistent with a diagnosis,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 14:33:26,,1312984591,7/2/2014 14:32:59,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],clinical signs,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 14:48:26,,1312994359,7/2/2014 14:47:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],signs that were consistent with a diagnosis of,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 15:52:54,,1313033124,7/2/2014 15:52:20,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],THROMBOCYTOSIS signs diagnosis ESSENTIAL THROMBOCYTHEMIA,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 16:12:51,,1313045786,7/2/2014 16:12:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOSIS ESSENTIAL THROMBOCYTHEMIA,n/a,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 17:29:56,,1313103775,7/2/2014 17:29:02,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[SYMPTOM],[SYMPTOM],clinical signs,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 19:28:22,,1313218287,7/2/2014 19:27:55,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were consistent with a diagnosis of,NA,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 19:31:33,,1313221404,7/2/2014 19:30:40,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],THROMBOCYTOSIS diagnosis of ESSENTIAL THROMBOCYTHEMIA,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 22:36:38,,1313437329,7/2/2014 22:36:06,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[MANIFESTATION],[MANIFESTATION],consistent diagnosis,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 23:25:15,,1313475099,7/2/2014 23:24:28,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],THROMBOCYTOSIS consistent with diagnosis of ESSENTIAL THROMBOCYTHEMIA,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/2/2014 23:48:32,,1313491710,7/2/2014 23:48:16,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/3/2014 00:34:15,,1313513401,7/3/2014 00:33:21,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",clinical signs with a diagnosis of,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/3/2014 01:25:23,,1313544015,7/3/2014 01:24:50,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/3/2014 01:50:59,,1313560103,7/3/2014 01:50:12,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],THROMBOCYTOSIS diagnosis ESSENTIAL THROMBOCYTHEMIA,CAUSES,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187331,7/3/2014 01:51:51,,1313560594,7/3/2014 01:51:08,clixsense,1,20316161,CAN,NL,Paradise,47.55.71.247,[SYMPTOM],[SYMPTOM],clinical signs consistent with diagnosis,N/A,45,120,59,145,1,RO-disease_has_finding,901906,A dog with a myeloproliferative disorder and THROMBOCYTOSIS had clinical signs that were consistent with a diagnosis of ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
497187332,7/2/2014 14:10:55,,1312969645,7/2/2014 14:10:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms of,N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 14:28:08,,1312981004,7/2/2014 14:27:31,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"study examined self-reported symptoms of ANXIETY, and POSTTRAUMATIC STRESS DISORDER (PTSD)",n/a,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 14:42:33,,1312990619,7/2/2014 14:42:23,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 15:40:45,,1313025722,7/2/2014 15:40:04,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],"symptoms of ANXIETY, and POSTTRAUMATIC STRESS DISORDER",N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 16:22:43,,1313052451,7/2/2014 16:22:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"ANXIETY, POSTTRAUMATIC STRESS DISORDER",n/a,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 16:42:30,,1313065983,7/2/2014 16:41:59,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"symptoms of ANXIETY, and POSTTRAUMATIC STRESS DISORDER",n/a,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 17:33:23,,1313106846,7/2/2014 17:32:58,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 17:45:16,,1313119621,7/2/2014 17:45:01,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],258,dssdsdsd,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 22:32:38,,1313434860,7/2/2014 22:31:49,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],"ANXIETY, POSTTRAUMATIC STRESS DISORDER",N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 22:42:38,,1313440967,7/2/2014 22:42:07,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],self-reported symptoms,N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 22:51:07,,1313451548,7/2/2014 22:50:17,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[OTHER],[OTHER],symptoms of and,N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 23:16:00,,1313468364,7/2/2014 23:13:48,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"self-reported symptoms ANXIETY, POSTTRAUMATIC STRESS DISORDER",associated with,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/2/2014 23:48:45,,1313491838,7/2/2014 23:48:34,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM],[SYMPTOM],symptoms,n/a,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/3/2014 01:29:14,,1313546235,7/3/2014 01:28:34,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[SYMPTOM],[SYMPTOM],symptoms,N/A,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187332,7/3/2014 01:52:58,,1313561161,7/3/2014 01:51:52,clixsense,1.0,20316161,CAN,NL,Paradise,47.55.71.247,[NONE],[NONE],N/A,two different disorders,58,107,65,136,-1,RO-has_definitional_manifestation,904887,"This study examined self-reported symptoms of depression, ANXIETY, somatization, generalized distress, and POSTTRAUMATIC STRESS DISORDER (PTSD) in a community sample of 258 immigrants from Central America and Mexico and 329 native-born Mexican Americans and Anglo Americans",ANXIETY,POSTTRAUMATIC STRESS DISORDER
497187333,7/2/2014 14:33:50,,1312984907,7/2/2014 14:33:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[OTHER],[OTHER],other forms,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 15:16:40,,1313011214,7/2/2014 15:16:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[MANIFESTATION],[MANIFESTATION],MIGRAINES and other forms of HEADACHES,n/a,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 15:41:10,,1313025920,7/2/2014 15:40:46,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],MIGRAINES other forms of HEADACHES,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 16:45:19,,1313067985,7/2/2014 16:44:48,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],relieve MIGRAINES and other forms of HEADACHES,n/a,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 18:21:47,,1313154512,7/2/2014 18:21:03,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[IS_A],[IS_A],MIGRAINES and other forms of HEADACHES,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 19:25:43,,1313215671,7/2/2014 19:25:10,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],other forms,NA,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 19:32:52,,1313222730,7/2/2014 19:32:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],MIGRAINES and other forms of HEADACHES,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 21:45:43,,1313403532,7/2/2014 21:45:25,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],and other forms of,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 22:44:42,,1313442346,7/2/2014 22:44:30,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and other forms,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 23:16:24,,1313468662,7/2/2014 23:15:52,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A] [MANIFESTATION],"[MANIFESTATION]
[IS_A]",MIGRAINES and other forms of HEADACHES,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/2/2014 23:39:21,,1313485588,7/2/2014 23:38:51,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SYMPTOM] [PREVENTS],"[PREVENTS]
[SYMPTOM]",response relieve,n/a,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/3/2014 00:43:08,,1313517315,7/3/2014 00:42:09,prodege,1.0,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],and other forms of,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/3/2014 01:00:10,,1313527125,7/3/2014 00:59:26,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[MANIFESTATION] [SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",other forms of,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/3/2014 01:20:12,,1313540618,7/3/2014 01:19:30,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[PREVENTS],[PREVENTS],relieve,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187333,7/3/2014 01:35:58,,1313550804,7/3/2014 01:33:29,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[IS_A],[IS_A],and subsequently relieve MIGRAINES and other forms HEADACHES,N/A,317,288,326,297,-1,RO-has_definitional_manifestation,904697,"Current research supports the hypothesis that migraines are a response to a pineal circadian irregularity in which the administration of melatonin normalizes this circadian cycle; i.e., melatonin may play a role in resynchronizing biological rhythms to lifestyle and subsequently relieve MIGRAINES and other forms of HEADACHES",HEADACHES,MIGRAINES
497187334,7/2/2014 13:48:52,,1312954920,7/2/2014 13:48:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[PART_OF],[PART_OF],CHILDHOOD OBESITY,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 15:03:14,,1313002824,7/2/2014 15:03:01,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OBESITY CHILDHOOD,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 15:18:03,,1313012232,7/2/2014 15:16:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"OBESITY morbidity, CHILDHOOD OBESITY",n/a,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 15:44:05,,1313027606,7/2/2014 15:43:30,instagc,1.0,21838928,GBR,"","",31.51.188.207,[PART_OF],[PART_OF],OBESITY CHILDHOOD OBESITY account for share,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 16:39:26,,1313063973,7/2/2014 16:39:02,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[CAUSES],[CAUSES],OBESITY predicts persistence of CHILDHOOD OBESITY,n/a,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 17:35:47,,1313109244,7/2/2014 17:35:13,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],account for,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 21:50:26,,1313406802,7/2/2014 21:50:12,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],OBESITY,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 22:24:54,,1313429843,7/2/2014 22:24:10,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],OBESITY CHILDHOOD OBESITY,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 22:34:07,,1313435739,7/2/2014 22:33:42,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[CAUSES],[CAUSES],predicts,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 23:13:47,,1313466743,7/2/2014 23:12:46,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],severity OBESITY persistence CHILDHOOD OBESITY account disproportionate adult obesity,associated with,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/2/2014 23:44:44,,1313489423,7/2/2014 23:43:37,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES] [PART_OF],"[CAUSES]
[PART_OF]",severity,n/a,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/3/2014 01:30:38,,1313546998,7/3/2014 01:27:56,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"extent that the severity of OBESITY predicts morbidity, persistence CHILDHOOD OBESITY may be expected to account for disproportionate share of adult obesity",N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/3/2014 01:38:32,,1313552391,7/3/2014 01:37:52,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],disproportionate share of the adult sequelae of obesity,N/A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/3/2014 01:54:32,,1313561890,7/3/2014 01:52:42,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[IS_A],[IS_A],OBESITY predicts CHILDHOOD OBESITY,IS_A,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187334,7/3/2014 02:08:19,,1313570463,7/3/2014 02:07:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OBESITY CHILDHOOD OBESITY,n/a,46,89,53,106,-1,RO-has_definitional_manifestation,904518,"Therefore, to the extent that the severity of OBESITY predicts morbidity, persistence of CHILDHOOD OBESITY may be expected to account for a disproportionate share of the adult sequelae of obesity",OBESITY,CHILDHOOD OBESITY
497187335,7/2/2014 14:04:33,,1312965643,7/2/2014 14:03:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[MANIFESTATION],[MANIFESTATION],--DIFFUSE LESIONS,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 14:29:06,,1312981712,7/2/2014 14:28:33,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],characterized,n/a,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 14:29:24,,1312981948,7/2/2014 14:29:02,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],--DIFFUSE LESIONS,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 14:45:59,,1312992815,7/2/2014 14:45:02,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPHANGIOMATOSIS --DIFFUSE LESIONS,n/a,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 15:47:51,,1313029943,7/2/2014 15:47:25,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],LYMPHANGIOMATOSIS --DIFFUSE LESIONS,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 16:26:46,,1313055105,7/2/2014 16:26:06,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS,n/a,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 17:32:24,,1313105908,7/2/2014 17:31:45,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[PART_OF],[PART_OF],One of them is,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 17:42:37,,1313116568,7/2/2014 17:42:24,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],phenomenon,dsdsdsds,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 17:51:27,,1313126180,7/2/2014 17:50:51,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],characterized,dssdsdds,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 18:15:59,,1313149341,7/2/2014 18:15:10,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[IS_A],[IS_A],One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 19:17:17,,1313207473,7/2/2014 19:16:34,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[OTHER],[OTHER],LYMPHANGIOMATOSIS --DIFFUSE LESIONS,na,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 19:28:34,,1313218447,7/2/2014 19:27:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized by,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 19:39:17,,1313228737,7/2/2014 19:38:52,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[IS_A],[IS_A],is,NA,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 22:27:42,,1313431515,7/2/2014 22:27:06,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],LYMPHANGIOMATOSIS --DIFFUSE LESIONS,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187335,7/2/2014 22:38:05,,1313438212,7/2/2014 22:37:46,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],characterized,N/A,35,15,50,32,1,RO-disease_has_finding,901790,One of them is LYMPHANGIOMATOSIS --DIFFUSE LESIONS characterized primarily by an increased number of complex anastomosing lymphatic channels in which dilatation is secondary phenomenon,DIFFUSE LESIONS,LYMPHANGIOMATOSIS
497187336,7/2/2014 14:02:52,,1312964620,7/2/2014 14:02:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],the most prevalent headache was,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 14:41:21,,1312989794,7/2/2014 14:41:07,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most prevalent headache,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 15:46:27,,1313029011,7/2/2014 15:45:29,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],HEADACHE was MIGRAINE,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 15:53:59,,1313033780,7/2/2014 15:51:16,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,[IS_A] [MANIFESTATION],"[MANIFESTATION]
[IS_A]",most prevalent was,I havent selected NONE,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 16:09:46,,1313043772,7/2/2014 16:09:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE MIGRAINE,n/a,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 16:23:07,,1313052647,7/2/2014 16:22:33,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most prevalent headache was MIGRAINE,n/a,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 17:35:12,,1313108681,7/2/2014 17:34:47,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[IS_A],[IS_A],most prevalent headache was,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 17:43:44,,1313117883,7/2/2014 17:43:27,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],of,dsdsds,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 22:45:25,,1313442862,7/2/2014 22:45:11,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[PART_OF],[PART_OF],most prevalent,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 22:45:43,,1313443091,7/2/2014 22:45:03,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],and the most prevalent headache,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 23:27:19,,1313476484,7/2/2014 23:26:19,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A] [CONTRAINDICATES],"[CONTRAINDICATES]
[IS_A]",HEADACHE most prevalent was MIGRAINE,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 23:39:46,,1313485917,7/2/2014 23:39:22,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[LOCATION],[LOCATION],found,n/a,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/2/2014 23:55:36,,1313495324,7/2/2014 23:54:57,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],most prevalent headache was,n/a,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/3/2014 00:39:42,,1313515683,7/3/2014 00:39:02,prodege,1.0,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],the most prevalent headache was,N/A,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187336,7/3/2014 00:49:01,,1313520521,7/3/2014 00:48:34,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],most prevalent headache,n/a,21,76,29,84,-1,RO-has_definitional_manifestation,904684,A high prevalence of HEADACHE was found and the most prevalent headache was MIGRAINE,HEADACHE,MIGRAINE
497187337,7/2/2014 14:00:56,,1312963401,7/2/2014 14:00:35,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common toxicities,N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 14:32:57,,1312984271,7/2/2014 14:32:45,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 15:28:48,,1313018509,7/2/2014 15:28:22,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],"toxicities were LEUKOPENIA, GRANULOCYTOPENIA,",N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 16:08:51,,1313043175,7/2/2014 16:08:40,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUKOPENIA, GRANULOCYTOPENIA, anaemia, oesophagitis,",n/a,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 16:43:22,,1313066590,7/2/2014 16:43:05,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA,",n/a,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 17:51:43,,1313126407,7/2/2014 17:51:06,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],"LEUKOPENIA,",dsdsds,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 19:22:31,,1313212504,7/2/2014 19:22:14,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA,",na,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 19:33:21,,1313223209,7/2/2014 19:32:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA,",They are both toxicities.,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 22:35:18,,1313436462,7/2/2014 22:34:53,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"LEUKOPENIA, GRANULOCYTOPENIA,",N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 22:42:47,,1313441041,7/2/2014 22:42:39,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common toxicities were,N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/2/2014 23:22:20,,1313473079,7/2/2014 23:21:45,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common,n/a,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/3/2014 00:46:30,,1313519063,7/3/2014 00:45:41,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common toxicities were,N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/3/2014 00:49:20,,1313520725,7/3/2014 00:49:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common toxicities were,na,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/3/2014 00:55:34,,1313524307,7/3/2014 00:54:20,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Common toxicities were,N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187337,7/3/2014 01:26:30,,1313544615,7/3/2014 01:25:24,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Common,N/A,23,35,33,51,-1,RO-has_definitional_manifestation,904744,"Common toxicities were LEUKOPENIA, GRANULOCYTOPENIA, anaemia, and radiation oesophagitis, with frequencies of grade &gt;or=3 toxicities of 71, 60, 24, and 19%, respectively",LEUKOPENIA,GRANULOCYTOPENIA
497187338,7/2/2014 13:46:25,,1312953228,7/2/2014 13:45:12,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, (among patients",N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 14:07:49,,1312967694,7/2/2014 14:07:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 14:37:10,,1312987085,7/2/2014 14:36:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 15:21:50,,1313014471,7/2/2014 15:20:47,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER],[OTHER],"experienced incidence of THROMBOCYTOPENIA, PANCYTOPENIA,",N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 16:24:01,,1313053235,7/2/2014 16:23:50,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THROMBOCYTOPENIA, PANCYTOPENIA,",n/a,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 17:06:25,,1313084912,7/2/2014 17:05:24,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(among patients with previously untreated CLL) and THROMBOCYTOPENIA, PANCYTOPENIA, and",N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 17:46:43,,1313121092,7/2/2014 17:45:33,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],and,sddsdsds,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 19:19:23,,1313209441,7/2/2014 19:18:46,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THROMBOCYTOPENIA, PANCYTOPENIA,",na,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 19:34:17,,1313224052,7/2/2014 19:33:22,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,They are different diseases mentioned in the same sentence.,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 19:34:44,,1313224493,7/2/2014 19:34:16,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 22:50:32,,1313450591,7/2/2014 22:50:23,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 23:22:52,,1313473406,7/2/2014 23:22:04,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"THROMBOCYTOPENIA, PANCYTOPENIA,",N/A,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 23:43:35,,1313488713,7/2/2014 23:42:12,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]","adverse effects, treated",n/a,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 23:54:17,,1313494659,7/2/2014 23:53:40,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187338,7/2/2014 23:58:40,,1313496731,7/2/2014 23:58:15,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,272,290,288,302,-1,RO-has_definitional_manifestation,904584,"1 ,   51   Compared with younger patients, patients ?70 years of age experienced higher incidence of grade 3 or 4 adverse effects, including neutropenia, febrile neutropenia, anemia, and pancytopenia (among patients with previously untreated CLL) and neutropenia, anemia, THROMBOCYTOPENIA, PANCYTOPENIA, and infections (among patients with previously treated CLL",THROMBOCYTOPENIA,PANCYTOPENIA
497187339,7/2/2014 14:39:34,,1312988680,7/2/2014 14:39:22,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],characterized,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 15:20:24,,1313013616,7/2/2014 15:19:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYELODYSPLASTIC SYNDROMES characterized INEFFECTIVE HEMATOPOIESIS,n/a,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 15:53:18,,1313033400,7/2/2014 15:52:55,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES characterized by INEFFECTIVE HEMATOPOIESIS,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 16:38:00,,1313062938,7/2/2014 16:37:29,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES are a group of diseases characterized by INEFFECTIVE HEMATOPOIESIS,n/a,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 17:33:43,,1313107163,7/2/2014 17:33:24,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[SYMPTOM],[SYMPTOM],characterized by,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 17:38:58,,1313112458,7/2/2014 17:38:33,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],cytopenias,dssdsd,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 19:20:27,,1313210482,7/2/2014 19:19:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES characterized by INEFFECTIVE HEMATOPOIESIS,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 19:33:47,,1313223633,7/2/2014 19:33:24,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],characterized by,NA,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 19:39:30,,1313228926,7/2/2014 19:38:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 22:44:29,,1313442208,7/2/2014 22:44:17,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[MANIFESTATION],[MANIFESTATION],characterized by,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 23:17:04,,1313469118,7/2/2014 23:16:26,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES characterized by INEFFECTIVE HEMATOPOIESIS,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/2/2014 23:45:49,,1313490208,7/2/2014 23:45:26,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combination,n/a,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/3/2014 00:32:32,,1313512649,7/3/2014 00:31:36,prodege,1.0,2145087,USA,"","",184.53.6.188,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",characterized by,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/3/2014 00:45:01,,1313518249,7/3/2014 00:44:05,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],MYELODYSPLASTIC SYNDROMES heterogeneous group diseases characterized INEFFECTIVE HEMATOPOIESIS,manifestation,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187339,7/3/2014 01:01:19,,1313527758,7/3/2014 01:00:14,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",group of diseases characterized by,N/A,87,0,112,25,1,RO-disease_has_finding,901685,MYELODYSPLASTIC SYNDROMES (MDS) are a heterogeneous group of diseases characterized by INEFFECTIVE HEMATOPOIESIS presenting with peripheral cytopenias in combination with a hyperplastic bone marrow,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES
497187340,7/2/2014 14:38:40,,1312988052,7/2/2014 14:38:22,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list of diseases,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 15:54:57,,1313034426,7/2/2014 15:54:21,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e., LEUKOPENIA, GRANULOCYTOPENIA,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 16:27:48,,1313055768,7/2/2014 16:27:00,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[CONTRAINDICATES] [ASSOCIATED_WITH],"[CONTRAINDICATES]
[ASSOCIATED_WITH]","LEUKOPENIA, GRANULOCYTOPENIA,",n/a,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 17:34:03,,1313107486,7/2/2014 17:33:43,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 17:42:08,,1313115768,7/2/2014 17:41:54,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],with,dsdssdds,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 19:27:54,,1313217813,7/2/2014 19:27:37,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],"(i.e.,",NA,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 19:34:17,,1313224044,7/2/2014 19:33:52,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e.,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 22:47:48,,1313445780,7/2/2014 22:47:38,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e.,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 23:04:07,,1313460264,7/2/2014 23:02:54,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA,",associated with,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 23:14:10,,1313466996,7/2/2014 23:13:45,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"LEUKOPENIA, GRANULOCYTOPENIA,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/2/2014 23:41:38,,1313487326,7/2/2014 23:41:01,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compromised,n/a,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/3/2014 00:38:14,,1313515108,7/3/2014 00:37:39,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"(i.e., LEUKOPENIA, GRANULOCYTOPENIA,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/3/2014 01:32:13,,1313548078,7/3/2014 01:30:32,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"compromised bone marrow reserve (i.e.,",N/A,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/3/2014 01:51:54,,1313560621,7/3/2014 01:51:00,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION],[MANIFESTATION],"caution bone marrow reserve LEUKOPENIA, GRANULOCYTOPENIA,",MANIFESTATION,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187340,7/3/2014 02:10:34,,1313571859,7/3/2014 02:10:01,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUKOPENIA, GRANULOCYTOPENIA,",n/a,76,88,86,104,-1,RO-has_definitional_manifestation,904912,"1  Use with caution in patients with compromised bone marrow reserve (i.e., LEUKOPENIA, GRANULOCYTOPENIA, extensive bone marrow metastases, prior radiation therapy, or prior therapy with other cytotoxic agents",LEUKOPENIA,GRANULOCYTOPENIA
497187341,7/2/2014 14:08:36,,1312968171,7/2/2014 14:07:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resulted in and,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 14:40:38,,1312989379,7/2/2014 14:40:26,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 14:57:18,,1312999336,7/2/2014 14:56:57,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 15:39:42,,1313025117,7/2/2014 15:38:40,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 16:24:34,,1313053616,7/2/2014 16:24:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,n/a,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 16:44:08,,1313067149,7/2/2014 16:43:23,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,n/a,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 17:34:46,,1313108227,7/2/2014 17:34:26,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 17:41:20,,1313114921,7/2/2014 17:41:07,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[LOCATION],[LOCATION],treatment,sddsdssd,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 19:16:32,,1313206725,7/2/2014 19:16:08,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC,na,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 22:12:56,,1313422469,7/2/2014 22:12:15,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],THROMBOCYTOPENIA and HEMOLYTIC ANEMIA,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 22:44:15,,1313442064,7/2/2014 22:44:07,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/2/2014 23:19:18,,1313470714,7/2/2014 23:18:50,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],resulted,n/a,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/3/2014 00:28:28,,1313511017,7/3/2014 00:27:46,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment resulted resolution of and,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/3/2014 00:33:06,,1313512897,7/3/2014 00:32:37,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187341,7/3/2014 00:57:43,,1313525611,7/3/2014 00:56:57,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[PREVENTS],[PREVENTS],resolution,N/A,225,246,241,279,-1,RO-has_definitional_manifestation,904607,"Although renal dysfunction progressed to dialysis-dependent renal failure in one patient despite treatment with prednisolone and plasmapheresis but not in other, withdrawal of the treatment resulted in a prompt resolution of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA in both patients",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187342,7/2/2014 14:29:52,,1312982222,7/2/2014 14:29:38,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 14:48:45,,1312994503,7/2/2014 14:48:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 15:42:50,,1313026862,7/2/2014 15:42:30,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with LENNOX-GASTAUT SYNDROME,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 16:29:18,,1313056861,7/2/2014 16:29:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",SEIZURES LENNOX-GASTAUT SYNDROME,n/a,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 16:39:01,,1313063630,7/2/2014 16:38:31,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES associated with LENNOX-GASTAUT SYNDROME,n/a,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 17:42:26,,1313116370,7/2/2014 17:42:15,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 19:30:03,,1313219918,7/2/2014 19:29:38,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],associated with,NA,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 20:40:16,,1313357955,7/2/2014 20:39:52,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N?A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 22:34:52,,1313436146,7/2/2014 22:34:09,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],SEIZURES associated with LENNOX-GASTAUT SYNDROME,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 22:53:23,,1313452861,7/2/2014 22:53:11,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[PART_OF]",associated with,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 23:31:17,,1313479572,7/2/2014 23:30:58,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/2/2014 23:59:13,,1313496891,7/2/2014 23:58:42,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/3/2014 01:05:54,,1313530023,7/3/2014 01:04:51,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/3/2014 01:28:32,,1313545833,7/3/2014 01:27:37,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],demonstrated statistically,N/A,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187342,7/3/2014 01:48:57,,1313558925,7/3/2014 01:48:35,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],SEIZURES associated with LENNOX-GASTAUT SYNDROME,SYMPTOM,141,166,149,189,-1,RO-has_definitional_manifestation,904511,Rufinamide has demonstrated statistically significant efficacy as an adjunctive therapy in adult patients with epilepsy and in patients with SEIZURES associated with LENNOX-GASTAUT SYNDROME,SEIZURES,LENNOX-GASTAUT SYNDROME
497187343,7/2/2014 14:24:49,,1312978822,7/2/2014 14:24:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],"in general, in particular,",N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 14:41:55,,1312990196,7/2/2014 14:41:43,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"general, particular,",N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 15:19:07,,1313012916,7/2/2014 15:18:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HEADACHE in general, MIGRAINE",n/a,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 15:35:37,,1313022629,7/2/2014 15:35:12,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],"HEADACHE MIGRAINE in particular,",N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 16:46:21,,1313068696,7/2/2014 16:45:44,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[IS_A],[IS_A],"HEADACHE in general, and MIGRAINE in particular,",n/a,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 19:30:22,,1313220202,7/2/2014 19:30:05,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],"in general,",NA,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 22:09:45,,1313420440,7/2/2014 22:09:11,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],HEADACHE and MIGRAINE,N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 22:45:47,,1313443133,7/2/2014 22:45:38,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/2/2014 23:32:22,,1313480430,7/2/2014 23:32:04,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],treatment,n/a,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 01:26:57,,1313544899,7/3/2014 01:26:32,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[TREATS],[TREATS],treatment,N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 01:33:41,,1313549228,7/3/2014 01:33:10,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]","in particular,",N/A,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 01:46:50,,1313557677,7/3/2014 01:45:14,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[MANIFESTATION] [PART_OF],"[MANIFESTATION]
[PART_OF]","HEADACHE MIGRAINE in particular,",PART_OF,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 02:07:21,,1313569748,7/3/2014 02:06:35,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE MIGRAINE,n/a,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 02:12:55,,1313573319,7/3/2014 02:12:25,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE MIGRAINE,n/a,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187343,7/3/2014 03:01:44,,1313601210,7/3/2014 03:01:29,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],HEADACHE,NONE,32,57,40,65,-1,RO-has_definitional_manifestation,904695,"The history of the treatment of HEADACHE in general, and MIGRAINE in particular, spans the millennia, from the Neanderthal era to the Space Age",HEADACHE,MIGRAINE
497187344,7/2/2014 15:02:21,,1313002313,7/2/2014 15:02:05,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resembling,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 15:20:14,,1313013531,7/2/2014 15:18:49,instagc,1.0,21838928,GBR,"","",31.51.188.207,[NONE] [OTHER],"[OTHER]
[NONE]",N/A,One subject resembled another.,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 16:25:41,,1313054408,7/2/2014 16:25:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS PLAQUES WORINGER-KOLOPP DISEASE,n/a,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 16:29:50,,1313057302,7/2/2014 16:28:59,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS PLAQUES resembling WORINGER-KOLOPP DISEASE,n/a,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 17:10:49,,1313088107,7/2/2014 17:08:49,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[MANIFESTATION],[MANIFESTATION],CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 17:38:15,,1313111686,7/2/2014 17:37:59,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resembling,n/a,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 17:48:41,,1313123263,7/2/2014 17:48:11,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],PLAQUES,dsdsds,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 19:22:12,,1313212167,7/2/2014 19:20:44,neodev,1.0,18963376,GBR,A5,Bedford,92.6.226.182,[SYMPTOM],[SYMPTOM],CUTANEOUS PLAQUES resembling WORINGER-KOLOPP DISEASE,na,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 19:38:34,,1313228097,7/2/2014 19:38:12,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM] [OTHER],"[SYMPTOM]
[OTHER]",resembling,NA,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 19:42:32,,1313231519,7/2/2014 19:41:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resembling,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 22:24:09,,1313429347,7/2/2014 22:22:22,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],CUTANEOUS PLAQUES restricted to sites resembling WORINGER-KOLOPP DISEASE,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 22:39:37,,1313439115,7/2/2014 22:39:17,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resembling,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 22:58:09,,1313456324,7/2/2014 22:56:49,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],CUTANEOUS PLAQUES resembling WORINGER-KOLOPP DISEASE,location,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/2/2014 23:30:10,,1313478701,7/2/2014 23:29:37,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES] [SIDE_EFFECT],"[CAUSES]
[SIDE_EFFECT]",show leading,n/a,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187344,7/3/2014 00:38:30,,1313515182,7/3/2014 00:36:11,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES],[CAUSES],leading to the designation mycosis fungoides,N/A,10,95,27,118,-1,RO-disease_may_have_finding,902993,"Recently, CUTANEOUS PLAQUES of epidermotropic lymphocytes restricted to acral sites resembling WORINGER-KOLOPP DISEASE were reported to show T-cell clonality, leading to the designation mycosis fungoides palmaris et plantaris",CUTANEOUS PLAQUES,WORINGER-KOLOPP DISEASE
497187345,7/2/2014 13:59:41,,1312962499,7/2/2014 13:59:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with both and,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 14:28:33,,1312981257,7/2/2014 14:28:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with both,n/a,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 14:29:37,,1312982105,7/2/2014 14:29:24,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,seperate items,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 15:52:18,,1313032801,7/2/2014 15:51:47,instagc,1.0,21838928,GBR,"","",31.51.188.207,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",PSEUDOSEIZURES and EPILEPSY,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 16:26:26,,1313054926,7/2/2014 16:26:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PSEUDOSEIZURES EPILEPSY,n/a,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 16:35:08,,1313060997,7/2/2014 16:34:27,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with both PSEUDOSEIZURES and EPILEPSY,n/a,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 17:50:50,,1313125545,7/2/2014 17:50:19,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],(Pure,dsdsds,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 18:21:02,,1313153892,7/2/2014 18:19:42,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with both PSEUDOSEIZURES and EPILEPSY,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 19:32:08,,1313222077,7/2/2014 19:31:48,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],both,NA,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 22:41:36,,1313440408,7/2/2014 22:41:13,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 23:17:04,,1313469131,7/2/2014 23:16:00,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],both PSEUDOSEIZURES and EPILEPSY,associated with,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 23:18:16,,1313469936,7/2/2014 23:17:50,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],PSEUDOSEIZURES and EPILEPSY,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/2/2014 23:38:11,,1313484713,7/2/2014 23:37:48,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/3/2014 00:47:59,,1313519920,7/3/2014 00:47:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],patients with both,n/a,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187345,7/3/2014 01:24:48,,1313543639,7/3/2014 01:24:26,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],included,N/A,70,89,84,97,-1,RO-has_definitional_manifestation,904557,Patients with pseudoseizures only (Pure group) and patients with both PSEUDOSEIZURES and EPILEPSY (Mixed group) were included,PSEUDOSEIZURES,EPILEPSY
497187346,7/2/2014 14:33:37,,1312984746,7/2/2014 14:33:27,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 14:50:00,,1312995236,7/2/2014 14:49:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],dermatologic reactions,N/A,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 15:12:44,,1313008636,7/2/2014 15:11:57,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],These include,N/A,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 16:28:01,,1313055982,7/2/2014 16:27:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUKOPENIA, PANCYTOPENIA,",n/a,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 16:33:41,,1313060024,7/2/2014 16:33:07,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"These include LEUKOPENIA, PANCYTOPENIA,",n/a,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 17:32:57,,1313106464,7/2/2014 17:32:25,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 17:36:36,,1313110025,7/2/2014 17:36:03,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],thrombocytopenia,cxcxcxcxcx,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 22:26:28,,1313430811,7/2/2014 22:25:53,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"LEUKOPENIA, PANCYTOPENIA,",N/A,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 22:46:01,,1313443294,7/2/2014 22:45:48,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,N/A,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/2/2014 23:18:48,,1313470287,7/2/2014 23:18:13,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SIDE_EFFECT],[SIDE_EFFECT],effects,n/a,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/3/2014 00:44:41,,1313518093,7/3/2014 00:43:48,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(including,N/A,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/3/2014 01:57:50,,1313563658,7/3/2014 01:57:21,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],"dermatologic reactions LEUKOPENIA, PANCYTOPENIA,",SYMPTOM,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/3/2014 02:13:46,,1313573727,7/3/2014 02:12:58,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUKOPENIA, PANCYTOPENIA,",n/a,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/3/2014 02:14:21,,1313573996,7/3/2014 02:13:37,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"LEUKOPENIA, PANCYTOPENIA,",n/a,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187346,7/3/2014 03:01:28,,1313601064,7/3/2014 03:01:05,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],thrombocytopenia,NONE,429,458,439,470,-1,RO-has_definitional_manifestation,904581,"1   These include fever, rash or other severe dermatologic reactions (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome), vasculitis, arthralgia, myalgia, serum sickness, allergic pneumonitis, interstitial nephritis, acute renal insufficiency or failure, hepatitis, jaundice, acute hepatic necrosis or failure, anemia (including hemolytic and aplastic), thrombocytopenia (including thrombotic thrombocytopenic purpura), LEUKOPENIA, agranulocytosis, PANCYTOPENIA, and/or other hematologic effects",LEUKOPENIA,PANCYTOPENIA
497187347,7/2/2014 14:30:36,,1312982684,7/2/2014 14:30:22,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,different symptoms,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 15:10:16,,1313006925,7/2/2014 15:09:52,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 16:24:57,,1313053894,7/2/2014 16:24:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOCYTOSIS and NEUTROPHILIA,n/a,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 17:36:06,,1313109548,7/2/2014 17:35:49,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[NONE],[NONE],N/A,"list items, not related",82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 17:50:18,,1313124943,7/2/2014 17:49:43,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],positively,dssddsds,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 17:50:33,,1313125199,7/2/2014 17:50:02,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],associated,dsdssdds,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 18:56:15,,1313187527,7/2/2014 18:55:46,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEUKOCYTOSIS and NEUTROPHILIA,n/a,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 19:31:00,,1313220941,7/2/2014 19:30:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 19:40:43,,1313229932,7/2/2014 19:40:16,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 22:46:19,,1313443471,7/2/2014 22:46:03,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 22:47:38,,1313445461,7/2/2014 22:46:54,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with associated with and,N/A,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 23:24:27,,1313474475,7/2/2014 23:23:38,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],LEUKOCYTOSIS and NEUTROPHILIA,N/A,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 23:38:26,,1313484900,7/2/2014 23:38:12,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/2/2014 23:59:28,,1313496955,7/2/2014 23:59:14,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187347,7/3/2014 00:42:24,,1313516920,7/3/2014 00:41:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],negatively associated with,n/a,82,99,94,111,-1,RO-has_definitional_manifestation,904707,".0035) and positively associated with neutropenia, and negatively associated with LEUKOCYTOSIS and NEUTROPHILIA",LEUKOCYTOSIS,NEUTROPHILIA
497187348,7/2/2014 14:01:17,,1312963612,7/2/2014 14:00:57,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 14:29:27,,1312981986,7/2/2014 14:29:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 14:31:14,,1312983121,7/2/2014 14:30:55,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 15:18:47,,1313012756,7/2/2014 15:18:15,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],characterized by,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 15:20:40,,1313013826,7/2/2014 15:20:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA,",n/a,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 16:30:21,,1313057608,7/2/2014 16:29:51,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"disease characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA,",n/a,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 17:44:44,,1313119040,7/2/2014 17:44:31,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],hemolytic,dssdds,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 19:41:23,,1313230526,7/2/2014 19:41:04,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],by,NA,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 22:25:52,,1313430446,7/2/2014 22:24:54,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA,",N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 22:42:05,,1313440683,7/2/2014 22:41:50,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/2/2014 23:40:06,,1313486184,7/2/2014 23:39:48,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[IS_A],[IS_A],is a,n/a,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/3/2014 00:42:44,,1313517055,7/3/2014 00:42:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],that is characterized by,n/a,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/3/2014 01:21:39,,1313541698,7/3/2014 01:20:49,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES],[CAUSES],renal failure,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/3/2014 01:35:29,,1313550532,7/3/2014 01:34:30,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]",is characterized by,N/A,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187348,7/3/2014 01:45:10,,1313556678,7/3/2014 01:44:16,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],"hemolytic uremic syndrome disease characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA,",symptom,108,73,124,106,-1,RO-has_definitional_manifestation,904871,"Atypical hemolytic uremic syndrome is a disease that is characterized by MICROANGIOPATHIC HEMOLYTIC ANEMIA, THROMBOCYTOPENIA, and acute renal failure",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187349,7/2/2014 14:00:34,,1312963105,7/2/2014 13:59:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],with without,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 14:32:22,,1312983891,7/2/2014 14:31:57,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subjects,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 14:35:43,,1312986124,7/2/2014 14:35:27,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHE,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 15:20:51,,1313013915,7/2/2014 15:20:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE HEADACHE,n/a,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 15:49:15,,1313030876,7/2/2014 15:48:21,instagc,1.0,21838928,GBR,"","",31.51.188.207,[IS_A],[IS_A],MIGRAINE and HEADACHE,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 16:31:09,,1313058311,7/2/2014 16:30:23,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subjects with MIGRAINE subjects without HEADACHE,n/a,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 17:44:15,,1313118479,7/2/2014 17:44:01,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],pain,dsdsdsds,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 17:54:08,,1313129115,7/2/2014 17:53:57,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],evaluated,dsdsdsdsdsd,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 19:39:55,,1313229246,7/2/2014 19:39:35,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],and,NA,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 22:28:29,,1313432036,7/2/2014 22:27:43,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[IS_A],[IS_A],MIGRAINE and HEADACHE,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 22:49:02,,1313447934,7/2/2014 22:48:55,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/2/2014 23:35:25,,1313482673,7/2/2014 23:33:58,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[LOCATION] [ASSOCIATED_WITH],"[LOCATION]
[ASSOCIATED_WITH]",socioeconomic between,n/a,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/3/2014 00:36:38,,1313514471,7/3/2014 00:35:36,prodege,1,2145087,USA,"","",184.53.6.188,[IS_A],[IS_A],and,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/3/2014 00:43:44,,1313517635,7/3/2014 00:41:34,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],subjects with subjects without,N/A,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187349,7/3/2014 00:48:22,,1313520096,7/3/2014 00:46:42,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],555 subjects with MIGRAINE and low back pain 1005 subjects without HEADACHE low back pain,is a,325,257,333,265,-1,RO-has_definitional_manifestation,904598,"The socioeconomic impact was evaluated prospectively by the number of workdays missed between 1989 and 1992 in 436 subjects with migraine but without low back pain (M group), 590 subjects with low back pain but without migraine (L group), 555 subjects with MIGRAINE and low back pain (ML group), and in 1005 subjects without HEADACHE or low back pain (C group",HEADACHE,MIGRAINE
497187350,7/2/2014 13:49:41,,1312955420,7/2/2014 13:49:18,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clinical features,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 14:03:42,,1312965176,7/2/2014 14:02:54,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The clinical features of,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 14:34:38,,1312985453,7/2/2014 14:34:20,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,different symptoms,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 15:43:29,,1313027259,7/2/2014 15:42:51,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],features classified POLYMYALGIA RHEUMATICA; manifestations of PAIN,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 16:25:10,,1313054019,7/2/2014 16:24:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],POLYMYALGIA RHEUMATICA; PAIN,n/a,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 16:33:06,,1313059658,7/2/2014 16:32:09,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clinical features can be classified into: POLYMYALGIA RHEUMATICA; PAIN,n/a,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 17:44:30,,1313118786,7/2/2014 17:44:16,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],POLYMYALGIA,dsdsds,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 18:57:28,,1313188879,7/2/2014 18:56:52,prodege,1.0,9378607,GBR,U8,Edinburgh,94.1.221.80,[PART_OF],[PART_OF],GCA can be classified into: POLYMYALGIA RHEUMATICA;,n/a,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 19:40:15,,1313229465,7/2/2014 19:39:56,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],manifestations of,NA,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 22:41:49,,1313440570,7/2/2014 22:41:38,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],manifestations,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 23:20:25,,1313471564,7/2/2014 23:19:56,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],pain POLYMYALGIA RHEUMATICA;,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 23:26:07,,1313475628,7/2/2014 23:24:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GCA classified into: POLYMYALGIA RHEUMATICA; arteritic manifestations PAIN,associated with,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/2/2014 23:41:56,,1313487564,7/2/2014 23:41:39,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],classified,n/a,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/3/2014 00:41:21,,1313516349,7/3/2014 00:40:34,prodege,1.0,2145087,USA,"","",184.53.6.188,[ASSOCIATED_WITH],[ASSOCIATED_WITH],The clinical features of,N/A,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187350,7/3/2014 00:44:35,,1313518052,7/3/2014 00:43:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],arteritic manifestations of,n/a,248,192,252,214,-1,RO-has_definitional_manifestation,904769,"The clinical features of GCA can be classified into: (1) the systemic manifestations of malaise, weight loss, fever, night sweats and depression; (2) the proximal muscle pain and stiffness of POLYMYALGIA RHEUMATICA; (3) arteritic manifestations of PAIN or tenderness due to local inflammation; and (4) arteritic manifestations of ischaemia due to narrowing or occlusion of vessels",PAIN,POLYMYALGIA RHEUMATICA
497187351,7/2/2014 14:10:14,,1312969221,7/2/2014 14:09:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[PART_OF],[PART_OF],HEAT,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 14:37:51,,1312987547,7/2/2014 14:37:34,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],thus combining,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 15:11:12,,1313007567,7/2/2014 15:10:18,instagc,1.0,21838928,GBR,"","",31.51.188.207,[PART_OF],[PART_OF],better with HEAT,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 16:09:23,,1313043529,7/2/2014 16:09:14,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"HEAT EFFECT, HEAT",n/a,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 16:37:27,,1313062616,7/2/2014 16:36:18,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[TREATS],[TREATS],"better the HEAT EFFECT, combining VTAs with HEAT would be a logical approach",n/a,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 17:41:37,,1313115175,7/2/2014 17:41:22,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],the,dssdsdsdsd,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 17:53:19,,1313128186,7/2/2014 17:53:08,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],poorer,dsdsdsds,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 19:27:09,,1313217073,7/2/2014 19:26:51,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[PART_OF],[PART_OF],combining,NA,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 22:40:24,,1313439573,7/2/2014 22:40:06,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VTAs with HEAT,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 23:09:32,,1313463937,7/2/2014 23:08:12,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[PART_OF],[PART_OF],"HEAT EFFECT, thus combining HEAT",N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 23:21:57,,1313472782,7/2/2014 23:20:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[PART_OF],[PART_OF],"HEAT EFFECT, combining with HEAT",part of,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/2/2014 23:30:29,,1313478986,7/2/2014 23:30:12,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],combining,n/a,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/3/2014 00:38:56,,1313515361,7/3/2014 00:38:19,prodege,1.0,2145087,USA,"","",184.53.6.188,[CAUSES],[CAUSES],with,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/3/2014 00:48:40,,1313520321,7/3/2014 00:46:35,prodege,1,20472192,CAN,BC,Richmond,66.183.145.169,[CAUSES],[CAUSES],combining,n/a,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187351,7/3/2014 00:58:11,,1313525946,7/3/2014 00:56:55,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",thus combining with,N/A,92,54,96,65,-1,RO-has_causative_agent,903764,"Generally, the poorer the blood supply the better the HEAT EFFECT, thus combining VTAs with HEAT would appear to be a logical approach",HEAT,HEAT EFFECT
497187352,7/2/2014 14:09:29,,1312968726,7/2/2014 14:08:37,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],patients with,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 14:37:33,,1312987337,7/2/2014 14:37:11,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 15:22:32,,1313014885,7/2/2014 15:21:51,instagc,1.0,21838928,GBR,"","",31.51.188.207,[CAUSES],[CAUSES],VACCINIA VIRUS patients with VACCINIA,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 16:22:32,,1313052362,7/2/2014 16:21:17,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],environmental survival of VACCINIA VIRUS offers recommendations for management of patients with VACCINIA,n/a,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 16:23:01,,1313052610,7/2/2014 16:22:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],VACCINIA VIRUS VACCINIA,n/a,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 17:50:00,,1313124655,7/2/2014 17:49:30,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],hospital-associated,dsdsdsds,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 17:53:30,,1313128420,7/2/2014 17:53:20,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],management,dsdsdsdsds,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 22:44:58,,1313442586,7/2/2014 22:44:00,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[MANIFESTATION],[MANIFESTATION],VACCINIA VIRUS patients with VACCINIA,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 22:47:36,,1313445437,7/2/2014 22:47:23,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],management,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 23:05:42,,1313461302,7/2/2014 23:04:08,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],survival VACCINIA VIRUS management patients VACCINIA,associated with,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 23:30:53,,1313479235,7/2/2014 23:30:02,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],VACCINIA VIRUS with VACCINIA,N/A,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/2/2014 23:33:20,,1313481220,7/2/2014 23:32:50,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PREVENTS],[PREVENTS],minimize,n/a,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/3/2014 00:46:38,,1313519129,7/3/2014 00:46:05,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],recommendations for the management of patients,n/a,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/3/2014 01:41:59,,1313554508,7/3/2014 01:41:06,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[CAUSES],[CAUSES],VACCINIA VIRUS VACCINIA minimize,causes,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187352,7/3/2014 02:12:00,,1313572749,7/3/2014 02:11:02,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],VACCINIA VIRUS VACCINIA,n/a,124,202,138,210,-1,RO-has_causative_agent,903616,"This paper describes hospital-associated spread of vaccinia virus infection, supplies data on the environmental survival of VACCINIA VIRUS and offers recommendations for the management of patients with VACCINIA that may minimize the hazard of infection in other high-risk patients",VACCINIA VIRUS,VACCINIA
497187353,7/2/2014 15:03:00,,1313002624,7/2/2014 15:02:39,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],characterized,N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 15:38:39,,1313024513,7/2/2014 15:38:11,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],"MCCUNE-ALBRIGHT SYNDROME characterized by PRECOCIOUS PUBERTY,",N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 16:09:12,,1313043389,7/2/2014 16:08:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"MCCUNE-ALBRIGHT SYNDROME PRECOCIOUS PUBERTY,",n/a,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 16:23:54,,1313053153,7/2/2014 16:23:08,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],"MCCUNE-ALBRIGHT SYNDROME is a rare disorder characterized by PRECOCIOUS PUBERTY,",n/a,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 17:43:00,,1313117023,7/2/2014 17:42:39,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION] [LOCATION],"[LOCATION]
[MANIFESTATION]",caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait,dssddss,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 19:33:50,,1313223684,7/2/2014 19:33:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",characterized by,N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 19:35:58,,1313225603,7/2/2014 19:35:11,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],characterized by,NA,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 20:38:07,,1313356238,7/2/2014 20:37:41,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[MANIFESTATION],[MANIFESTATION],characterized by,N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 22:27:06,,1313431138,7/2/2014 22:26:29,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]","MCCUNE-ALBRIGHT SYNDROME characterized by PRECOCIOUS PUBERTY,",N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 22:48:54,,1313447744,7/2/2014 22:48:45,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized,N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 22:59:33,,1313457133,7/2/2014 22:58:11,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]","MCCUNE-ALBRIGHT SYNDROME (MAS) characterized classic triad PRECOCIOUS PUBERTY,",symptom and/or manifestation,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/2/2014 23:48:14,,1313491557,7/2/2014 23:47:24,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[IS_A],[IS_A],is a,n/a,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/3/2014 00:29:32,,1313511473,7/3/2014 00:28:32,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",characterized by,N/A,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/3/2014 00:46:35,,1313519090,7/3/2014 00:44:08,prodege,1.0,20472192,CAN,BC,Richmond,66.183.145.169,[SYMPTOM],[SYMPTOM],characterized,no,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187353,7/3/2014 00:49:51,,1313521034,7/3/2014 00:49:22,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SYMPTOM],[SYMPTOM],characterized by the classic,n/a,88,0,106,24,1,RO-disease_has_finding,901704,"MCCUNE-ALBRIGHT SYNDROME (MAS) is a rare disorder characterized by the classic triad of PRECOCIOUS PUBERTY, polyostotic fibrous dysplasia and caf鐃緒申鐃緒申羝�申��申鐃処�鐃順�鐃初姐�渇���申鐃緒申鐃緒申羝�申��申鐃初�膩������括�鐃順�����鰹申鐃�ait spots",PRECOCIOUS PUBERTY,MCCUNE-ALBRIGHT SYNDROME
497187354,7/2/2014 14:50:56,,1312995750,7/2/2014 14:50:28,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],all cases of,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 15:04:14,,1313003349,7/2/2014 15:03:57,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[ASSOCIATED_WITH],[ASSOCIATED_WITH],constitutes of all cases,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 15:34:09,,1313021789,7/2/2014 15:33:38,instagc,1.0,21838928,GBR,"","",31.51.188.207,[PART_OF],[PART_OF],MALE INFERTILITY constitutes cases of INFERTILITY,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 16:23:25,,1313052827,7/2/2014 16:23:03,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALE INFERTILITY INFERTILITY,n/a,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 17:43:26,,1313117472,7/2/2014 17:43:12,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],INFERTILITY,dssddssd,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 19:29:07,,1313219040,7/2/2014 19:28:34,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],MALE INFERTILITY constitutes 35% cases INFERTILITY,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 22:19:36,,1313426571,7/2/2014 22:18:50,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],MALE INFERTILITY constitutes 35% of INFERTILITY,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 22:48:02,,1313446183,7/2/2014 22:47:49,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[CAUSES],[CAUSES],cases of,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 23:20:38,,1313471791,7/2/2014 23:19:28,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALE INFERTILITY constitutes 35% all cases INFERTILITY,associated with,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/2/2014 23:24:48,,1313474688,7/2/2014 23:24:23,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[LOCATION] [PART_OF],"[LOCATION]
[PART_OF]",In constitutes,n/a,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/3/2014 00:41:28,,1313516386,7/3/2014 00:40:06,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[IS_A],[IS_A],constitutes about 35% of all cases,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/3/2014 00:53:03,,1313522885,7/3/2014 00:52:26,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[CAUSES],[CAUSES],constitutes about 35%,N/A,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/3/2014 01:42:53,,1313555216,7/3/2014 01:42:00,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[PART_OF],[PART_OF],MALE INFERTILITY constitutes 35% INFERTILITY,part_of,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/3/2014 02:09:13,,1313570975,7/3/2014 02:08:32,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALE INFERTILITY INFERTILITY,n/a,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187354,7/3/2014 02:10:19,,1313571655,7/3/2014 02:09:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],MALE INFERTILITY INFERTILITY,n/a,68,13,79,29,-1,RO-has_definitional_manifestation,904872,"In Pakistan, MALE INFERTILITY constitutes about 35% of all cases of INFERTILITY",INFERTILITY,MALE INFERTILITY
497187355,7/2/2014 14:07:24,,1312967405,7/2/2014 14:07:05,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the presence of and,N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 14:35:26,,1312985955,7/2/2014 14:35:14,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,separate,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 15:11:55,,1313008044,7/2/2014 15:11:12,instagc,1.0,21838928,GBR,"","",31.51.188.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the presence of diagnosed,N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 16:29:04,,1313056722,7/2/2014 16:28:25,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,",n/a,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 16:34:26,,1313060595,7/2/2014 16:33:42,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,",n/a,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 17:49:11,,1313123805,7/2/2014 17:48:42,tremorgames,1.0,17552229,GBR,H9,London,109.154.7.94,[SYMPTOM],[SYMPTOM],THROMBOCYTOPENIA,dssdsdsd,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 19:26:17,,1313216242,7/2/2014 19:25:38,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THROMBOCYTOPENIA MICROANGIOPATHIC HEMOLYTIC ANEMIA,",N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 20:39:21,,1313357148,7/2/2014 20:38:37,neodev,1.0,18755947,GBR,H2,Accrington,80.47.187.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence of THROMBOCYTOPENIA and MICROANGIOPATHIC,N?A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 22:33:10,,1313435187,7/2/2014 22:32:39,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,",N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 22:49:48,,1313449297,7/2/2014 22:49:14,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/2/2014 23:47:23,,1313491204,7/2/2014 23:47:11,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,n/a,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/3/2014 00:02:40,,1313498574,7/3/2014 00:01:55,neodev,1.0,15848372,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/3/2014 01:23:54,,1313543095,7/3/2014 01:23:11,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Based on the presence THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA,",N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/3/2014 01:24:25,,1313543431,7/3/2014 01:23:38,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[MANIFESTATION] [DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",presence diagnosed treated,N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187355,7/3/2014 01:36:11,,1313550975,7/3/2014 01:35:34,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],presence of and,N/A,25,46,41,79,-1,RO-has_definitional_manifestation,904507,"Based on the presence of THROMBOCYTOPENIA and MICROANGIOPATHIC HEMOLYTIC ANEMIA, and with the exclusion of other known causes, the patient was diagnosed with thrombotic microangiopathy and successfully treated with plasma exchange and intravenous glucocorticoids",THROMBOCYTOPENIA,MICROANGIOPATHIC HEMOLYTIC ANEMIA
497187356,7/2/2014 14:23:57,,1312978234,7/2/2014 14:23:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],incidence of,N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 14:36:53,,1312986891,7/2/2014 14:36:33,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[NONE],[NONE],N/A,list,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 15:45:27,,1313028493,7/2/2014 15:44:42,instagc,1.0,21838928,GBR,"","",31.51.188.207,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]","incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, neutropenia",N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 16:25:15,,1313054084,7/2/2014 16:24:29,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"incidence of NEUTROPENIA, FEBRILE NEUTROPENIA,",n/a,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 16:26:47,,1313055133,7/2/2014 16:26:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"NEUTROPENIA, FEBRILE NEUTROPENIA,",n/a,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 17:43:11,,1313117172,7/2/2014 17:43:01,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[MANIFESTATION],[MANIFESTATION],we,dsdssdds,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 19:38:50,,1313228362,7/2/2014 19:38:35,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[OTHER],[OTHER],incidence,NA,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 22:10:20,,1313420837,7/2/2014 22:09:46,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[OTHER],[OTHER],"NEUTROPENIA, FEBRILE NEUTROPENIA, and",N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 22:52:38,,1313452421,7/2/2014 22:52:30,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/2/2014 23:20:36,,1313471750,7/2/2014 23:20:16,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationship,n/a,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/3/2014 00:52:25,,1313522490,7/3/2014 00:51:31,clixsense,1.0,10428985,GBR,M3,South Petherton,86.186.150.111,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationship of febrile neutropenia,N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/3/2014 01:25:55,,1313544289,7/3/2014 01:23:55,neodev,1.0,20929875,USA,MA,Boston,71.174.181.181,[NONE],[NONE],N/A,I couldNOT safely assume that these 2 conditions tend to appear together...rather that the study is looing for 1 or the other..or even other conditions.,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/3/2014 01:37:47,,1313551881,7/3/2014 01:36:29,onestopgpt,1.0,21275875,CAN,ON,Hamilton,216.209.129.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the incidence of,N/A,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/3/2014 01:59:50,,1313564881,7/3/2014 01:58:51,instagc,1.0,23149109,USA,NC,Durham,75.189.206.205,[SYMPTOM],[SYMPTOM],"incidence of NEUTROPENIA, FEBRILE NEUTROPENIA,",sYMPTOM,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187356,7/3/2014 02:05:59,,1313568863,7/3/2014 02:04:45,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"NEUTROPENIA, FEBRILE NEUTROPENIA,",n/a,53,66,64,85,-1,RO-has_definitional_manifestation,904600,"In the present study, we determined the incidence of NEUTROPENIA, FEBRILE NEUTROPENIA, and the relationship of febrile neutropenia to grade III/IV neutropenia and dose modification, in a large university patient population",NEUTROPENIA,FEBRILE NEUTROPENIA
497187357,7/2/2014 14:36:18,,1312986492,7/2/2014 14:35:57,fepcrowdflower,1.0,17940235,GBR,X5,Cardiff,176.252.22.6,[SYMPTOM],[SYMPTOM],alert possibility,N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 15:54:18,,1313034016,7/2/2014 15:53:50,instagc,1.0,21838928,GBR,"","",31.51.188.207,[SYMPTOM],[SYMPTOM],"with THROMBOCYTOPENIA possibility of KASABACH-MERRITT SYNDROME,",N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 15:57:15,,1313035852,7/2/2014 15:55:48,clixsense,1.0,27812714,NLD,06,Tilburg,84.31.160.155,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",should alert,n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 16:28:25,,1313056226,7/2/2014 16:28:14,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THROMBOCYTOPENIA KASABACH-MERRITT SYNDROME,",n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 16:41:26,,1313065299,7/2/2014 16:40:42,prodege,1.0,7899370,USA,MI,Bay City,71.13.81.162,[SYMPTOM],[SYMPTOM],"THROMBOCYTOPENIA should alert orthopaedist to the possibility of KASABACH-MERRITT SYNDROME,",n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 17:08:48,,1313086621,7/2/2014 17:06:27,neodev,1.0,20929875,USA,MA,Boston,140.241.0.20,[MANIFESTATION],[MANIFESTATION],"levels associated with THROMBOCYTOPENIA should alert orthopaedist to possibility of KASABACH-MERRITT SYNDROME,",N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 17:38:35,,1313112071,7/2/2014 17:38:16,prodege,1.0,17350748,CAN,ON,Cornwall,216.221.74.212,[ASSOCIATED_WITH],[ASSOCIATED_WITH],possibility of,n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 17:41:05,,1313114663,7/2/2014 17:40:46,prodege,1.0,18960400,GBR,H9,London,109.154.7.94,[CONTRAINDICATES],[CONTRAINDICATES],possibility,dsdssd,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 19:33:23,,1313223253,7/2/2014 19:32:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],should alert to the possibility of,N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 19:42:53,,1313231818,7/2/2014 19:42:14,prizezombie,1.0,19082757,USA,AL,Birmingham,138.26.152.5,[SYMPTOM],[SYMPTOM],possibility of,NA,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 22:12:14,,1313422071,7/2/2014 22:11:22,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.40.77,[SYMPTOM],[SYMPTOM],"THROMBOCYTOPENIA to possibility of KASABACH-MERRITT SYNDROME,",N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 22:36:05,,1313436935,7/2/2014 22:35:37,neodev,1.0,21241714,CAN,ON,Kitchener,216.58.1.155,[SYMPTOM],[SYMPTOM],alert,N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/2/2014 23:36:32,,1313483457,7/2/2014 23:35:55,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/3/2014 00:35:30,,1313514021,7/3/2014 00:33:17,prodege,1.0,2145087,USA,"","",184.53.6.188,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",should alert the orthopaedist to the possibility of,N/A,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
497187357,7/3/2014 00:43:12,,1313517354,7/3/2014 00:42:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[SIDE_EFFECT],[SIDE_EFFECT],should alert the orthopaedist to the possibility,n/a,59,191,75,216,-1,RO-has_definitional_manifestation,904766,"Decreased hematocrit and fibrinogen levels associated with THROMBOCYTOPENIA and prolonged prothrombin time and partial thromboplastin time should alert the orthopaedist to the possibility of KASABACH-MERRITT SYNDROME, and prompt hematologic consultation should be obtained",THROMBOCYTOPENIA,KASABACH-MERRITT SYNDROME
